8. Список литературы

1. Singer M., Deutschman C.S., Seymour C.W. et al. The Third International Consensus defnitions for sepsis and septic shock (Sepsis-3)// JAMA. – 2016. – Vol. 315, №8. – P. 801-810. 2. Сепсис: классификация клинико-диагностическая концепция и лечение. 4-е издание, дополненное и переработанное. Под ред. Б.Р. Гельфанда. — М.: ООО «МИА-МЕД», 2017. - 408 с. 3. WHO. Sepsis: key facts. April 19, 2018. https://www.who.int/news-room/ factsheets/detail/sepsis (accessed Nov 28, 2019). 4. Vincent J-L. Dear SIRS, I’m sorry to say that. I don’t like you// Crit Care Med.- 1997; 25:1765- 1768. 5. Vincent J-L, Rello J., Marshall J. et al. International study on the prevalence and outcome of infection in ICU. J A M A, 2009, vol.302, 2323- 2329. Pmid 19952319 6. Melamed A. The burden of sepsis-associated mortality in USA from 1999 to 2005: an analysis of multiple-cause-of-death date. Crit Care 2009; 13: R28 7. Vincent JL, Sakr Y, Singer M, et al. Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017. JAMA. 2020;323(15):1478-1487. doi:10.1001/jama.2020.2717 8. Flaatten H. Epidemiology of sepsis in Norway in 1999.Crit Care 2004;8:180-184 9. Руднов В.А., Бельский Д.В., Дехнич А.В. и др. Исследовательская группа РИОРИТа. Распространенность инфекций в отделения реанимации России//Клиническая Микробиология и Антимикробная Химиотерапия. 2011; 13(4):294-303 10. Козлов Р.С. Азизов И.С., Дехнич А.В., Иванчик Н.В., Кузьменков А.Ю., Мартинович А.А., Микотина А.В., Сухорукова М.В., Трушин И.В., Эйдельштейн М.В In vitro чувствительность к биапенему и другим карбапенемам клинических изолятов Pseudomonas aeruginosa, Acinetobacter spp. и представителей порядка Enterobacterales, выделенных у госпитализированных пациентов в различных регионах России. Клиническая микробиология и антимикробная химиотерапия. 2021; 23(3):280 - 291. DOI: 10.36488/cmac.2021.3.280-291 11. Кузьменков А.Ю., Виноградова А.Г., Трушин И.В., Эдельштейн М.В., Авраменко А.А., Дехнич А.В., Козлов Р.С. АMRmap – система мониторинга антибиотикорезистентности в России//Клиническая микробиология и антимикробная химиотерапия. 2021; 23(2):198-204. 10.36488/cmac.2021.2.198-204 12. Karlsson S., Varpula M., Ruokonen E. et al. Incidence, treatment and outcome of severe sepsis in ICU-treated adults in Finland: Finnsepsis study. Intensive Care Med 2007;33: 435-443 13. van Gestel A., Bakker J., Veraart CP. Et al. Prevalence and incidence of severe sepsis in Dutch ICU. Crit Care 2004; 8:153-162 88 14. Bernajo-Martin JF., de Lejantaza D., Rello G. et al. Th1 and Th17 hypercytokinemia as early host response segnature in severe pandemic influenza. Crit Care 2009; 13:R201 15. Bernajo-Martin JF., Atevala G., de Lejantaza D., et al. Persistance of proinflammatory response after severe respiratory syncytial virus disease in children. J Allergy Clin Immunol 2007;119:1547-1550 16. Cameron C., Cameron M., Bernajo-Martin JF. Et al. Gene expression annalysis of host innate immune response during lethal H5N1infection in ferrets J Virol 2008; 82:11308 -11317 17. Cameron M., Bernajo-Martin JF., Danesh A. Human pathogenesis of severe acute respiratory syndrome(SARS). 2008;133:13-19 18. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China. N Engl J Med. 2020;382:727–33 19. Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy. JAMA. 2020;323:1545 20. Б.А.Джантемиров, М.Б.Темрезов, А.С.Джанкезов. Сепсис. Теория и клиническая практика. Клинические лекции.-сИз-во «Эстен Медикал». - СПб.- 2021.- 182 с. 30- Guillermo Ortiz-Ruiz, Carmelo Dueñas-Castell. Sepsis. - 2018.- 3 еd., -171 p. -Springer, New York, DOI: https://doi.org/10.1007/978-1-4939-7334-7 21. Guillermo Ortiz-Ruiz, Carmelo Dueñas-Castell. Sepsis. - 2018.- 3 еd., -171 p. - Springer, New York, DOI: https://doi.org/10.1007/978-1-4939-7334-7. 22. Bone R.С. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. // Critical Care Medicine1996; vol. 24, P. 163-72 23. Deitch E.A., Vincent J.-l.., Windsor A. Sepsis and multiple organ dysfunction: a multidisciplinary approach. W.B. Saunders; 2002. 24. Matics T.J., Sanchez-Pinto L.N. Adaptation and validation of a pediatric sequential organ failure assessment score and evaluation of the Sepsis-3 definitions in critically ill children. JAMA Pediatr., 2017, vol. 171, pp. e172352. 25. Singer M., De Santis V., Vitale D. et al. Multiorgan failure is an adptive, endorinemediated, metabolic response to overwhelming systemic inflammation. Lancet 2004; 364:545-548. 26. Wunderink R., Waterer G. Genetics of sepsis and pneumonia. Curr Opin Care 2003; 9:384-389. 27. Sorensen TI., Nielsen GG., Andersen PK. Et al. Genetic and environmental influence on premature deathin audult adoptees. NEJM 1988; 318:727-732. 28. Martin G., Mannino D., Eaton S. et al. Epidemiology of sepsis in the United States from 1979 through 2000//NEJM.- 2003; 348:1546-1554 29. Fleischmann C, Scherag A, Adhikari NK, et al. Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations. Am J Respir Crit Care Med 2016; 193(3): 259-72. 30. Fleischmann-Struzek C, Goldfarb DM, Schlattmann P, Schlapbach LJ, Reinhart K, Kissoon N. The global burden of paediatric and neonatal sepsis: a systematic review. The Lancet Respiratory medicine 2018; 6(3): 223-30 89 31. Global report on the epidemiology and burden of sepsis: current evidence, identifying gaps and future directions. Geneva: World Health Organization; 2020 32. Vincent J-L, Highlighting the huge global burden of sepsis, Anaesthesia Critical Care & Pain Medicine, Volume 39, Issue 2, 2020, Pages 171-172 33. Imaeda, T., Nakada, Ta., Takahashi, N. et al. Trends in the incidence and outcome of sepsis using data from a Japanese nationwide medical claims database-the Japan Sepsis Alliance (JaSA) study group-. Crit Care 25, 338 (2021). https://doi.org/10.1186/s13054-021-03762-8 34. T.Yan et al. Hospital-acquired lower respiratory tract infections among high risk hospitalized patients in a tertiary care teaching hospital in China: An economic burden analysis// Journal of Infection and Public Health 11 (2018) 507–513 35. Torio CM (AHRQ), Andrews RM (AHRQ). National Inpatient Hospital Costs: The Most Expensive Conditions by Payer, 2011. HCUP Statistical Brief #160. August 2013. Agency for Healthcare Research and Quality, Rockville 36. Seymour CW, Liu VX, Iwashyna TJ et al (2016) Assessment of clinical criteria for sepsis: for the third international consensus definitions forsepsis and septic shock (Sepsis-3). JAMA 315(8):762–774 37. Evans L., Rhodes A., Alhazzani W., et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021// Critical Care Medicine. -2021; 49: e1063-e1143. doi: 10.1097/CCM.0000000000005337 38. Vincent J.L, Moreno R., Takala J., Willatts S., Mendonça A.De., Bruining H., Reinhart C.K., Suter P.M., Thijs L.G. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine//Intensive Care Med .1996 Jul;22(7):707-10. doi: 10.1007/BF01709751 39. Napolitano L.M. Sepsis 2018: definitions and guideline changes// Surg Infect (Larchmt).- 2018;19: 117-125; 40. Seymour C.W., Liu V.X., Iwashyna T.J. et al. Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (Sepsis-3)//JAMA.- 2016; 315(8):762–774 41. Angus D.C., Seymour Ch.W., Coopersmith C.M., Deutschman C.S., Klompas M., Levy M. M., Martin G.S., Osborn T.M., Rhee Ch., Watson R.S. A Framework for the Development and Interpretation of Different Sepsis Definitions and Clinical Criteria// Critical Care Medicine 44(3):p e113-e121, March 2016. DOI: 10.1097/CCM.0000000000001730 42. Fernando SM, Tran A, Taljaard M et al (2018) Prognostic accuracy of the quick sequential organ failure assessment for mortality in patients with suspected infection: a systematic review and meta-analysis. Ann Intern Med 168(4):266–275 43. Herwanto V, Shetty A, Nalos M et al (2019) Accuracy of quick sequential organ failure assessment score to predict sepsis mortality in 121 studies including 1,716,017 individuals: a systematic review and meta-analysis. Crit Care Explor. 1(9):e00434 44. Serafim R, Gomes JA, Salluh J et al (2018) A comparison of the Quick-SOFA and systemic inflammatory response syndrome criteria for the diagnosis of sepsis and 90 prediction of mortality: a systematic review and meta-analysis. Chest 153(3):646– 655 45. Cinel I, Kasapoglu US, Gul F et al (2020) The initial resuscitation of septic shock. J Crit Care 57:108–117 46. Toh C.H., Alhamdi Y., Abrams S.T. Current pathological and laboratory considerations in the diagnosis of disseminated intravascular coagulation// Ann Lab Med. -2016 Nov;36(6):505-12. http://doi: 10.3343/alm.2016.36.6.505 47. Iba T., Umemura Y., Wada H., Levy J.H. Roles of coagulation abnormalities and microthrombosis in sepsis: pathophysiology, diagnosis, and treatment// Arch Med Res. -2021 Nov;52(8):788-797. http://doi: 10.1016/j.arcmed.2021.07.003 48. Bugaev N., Como J.J., Golani G., Freeman J.J. et al. Thromboelastography and rotational thromboelastometry in bleeding patients with coagulopathy: Practice management guideline from the Eastern Association for the Surgery of Trauma// J Trauma Acute Care Surg. -2020 Dec;89(6):999-1017. http://doi: 10.1097/TA.0000000000002944 49. Tanaka K.A., Henderson R.A., Strauss E.R. Evolution of viscoelastic coagulation testing// Expert Rev Hematol. -2020 Jul;13(7):697-707. http://doi: 10.1080/17474086.2020.1758929 50. Samsudin I, Vasikaran SD. Clinical Utility and Measurement of Procalcitonin. Clin Biochem Rev. 2017;38(2):59-68 51. Schuetz P, Beishuizen A, Broyles M, Ferrer R, Gavazzi G, Gluck EH, González Del Castillo J, Jensen JU, Kanizsai PL, Kwa ALH, Krueger S, Luyt CE, Oppert M, Plebani M, Shlyapnikov SA, Toccafondi G, Townsend J, Welte T, Saeed K. Procalcitonin (PCT)-guided antibiotic stewardship: an international experts consensus on optimized clinical use. Clin Chem Lab Med. 2019;57(9):1308-1318 52. Meisner M. Pathobiochemistry and clinical use of procalcitonin. Clin Chim Acta. 2002;323:17–29 53. Bassetti S., Tschudin-Sutter S., Egli A., Osthoff M. Optimizing antibiotic therapies to reduce the risk of bacterial resistance// Eur J Intern Med. 2022: S0953-6205(22)00039-5 54. Zou Q., Wen W., Zhang X.C. Presepsin as a novel sepsis biomarker. World J Emerg Med. 2014;5(1):16–19. https://doi. Org/10.5847/wjem.j.issn.1920- 8642.2014.01.002 55. Wu J., Hu L., Zhang G., Wu F., He T. Accuracy of Presepsin in Sepsis Diagnosis: A Systematic Review and Meta-Analysis. PloS ONE. 2015;10(7):e0133057. https://doi.org/10.1371/ journal.pone.0133057 56. Zhang J., Hu Z.D., Song J., Shao J. Diagnostic Value of Presepsin for Sepsis: A Systematic Review and Meta- Analysis. Medicine (Baltimore). 2015;94(47):e2158. https://doi. Org/10.1097/MD.0000000000002158 57. Kirm TJ, Weinstein MP. Update on blood cultures: how to obtain, process, report, and interpret. Clin Microbiol Infect. 2013;19(6):513-520 58. Timbrook T.T., Morton J.B., McConeghy K.W., Caffrey A.R., Mylonakis E., LaPlante K.L. The effect of molecular rapid diagnostic testing on clinical outcomes in bloodstream infections: a systematic review and meta-analysis//Clin Infect Dis. – 2017; 64(1):15-23. Doi:10.1093/cid/ciw649 91 59. Яковлев С.В., Журавлева М.В., Проценко Д.Н., Белобородов В.Б., Брико Н.И., Брусина Е.Б., Гусаров В.Г., Елисеева Е.В., Замятин М.Н., Зырянов С.К., Кукес В.Г., Попов Д.А., Сидоренко С.В., Суворова М.П. Программа СКАТ (стратегия контроля антимикробной терапии) при оказании стационарной медицинской помощи// Методические рекомендации для лечебнопрофилактических учреждений Москвы. Хирургия. Приложение к журналу Consilium Medicum. 2017. № 1. С. 15-51 60. Peri AM, Stewart A, Hume A, Irwin A, Harris PNA. New Microbiological Techniques for the Diagnosis of Bacterial Infections and Sepsis in ICU Including Point of Care. Curr Infect Dis Rep. 2021;23(8):12 61. Белобородов В.Б., Голощапов О.В., Гусаров В.Г., Дехнич А.В., Замятин М.Н., Зубарева Н.А., Зырянов С.К., Камышова Д.А., Климко Н.Н., Козлов Р.С., Кулабухов В.В., Петрушин М.А., Полушин Ю.С., Попов Д.А., Руднов В.А., Сидоренко С.В., Соколов Д.В., Шлык И.В., Эйдельштейн М.В., Яковлев С.В. Методические рекомендации Российской некоммерческой общественной организации «Ассоциация анестезиологов-реаниматологов», Межрегиональной общественной организации «Альянс клинических химиотерапевтов и микробиологов», Межрегиональной ассоциации по клинической микробиологии и антимикробной химиотерапии (МАКМАХ), общественной организации «Российский Сепсис Форум» «Диагностика и антимикробная терапия инфекций, вызванных полирезистентными штаммами микроорганизмов» (обновление 2022 г.)// Вестник анестезиологии и реаниматологии. – 2022;19(2):84-114 62. Egi M., Ogura H., Yatabe T. et al. The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2020 (J-SSCG 2020)// Journal of Intensive Care.- 2021; 9:53 doi.org/10.1186/s40560-021-00555-7 63. Brouwer MC, Tunkel AR, McKhann GM 2nd, Van De Beek D. Brain abscess. N. Engl. J. Med. 2014; 371: 447–56 64. Maroldi R, Farina D, Ravanelli M, Lombardi D, Nicolai P. Emergency Imaging Assessment of Deep Neck Space Infections. Semin Ultrasound CT MR. 2012; 33: 432–42. 65. Внебольничная пневмония у взрослых. Клинические рекомендации.- Утверждены НПС МЗ РФ, 2021; 66. Клинические рекомендации – Пневмония (внебольничная)/-2022-2023-2024 (18.01.2022) – Клинические рекомендации.-Утверждены НПС МЗ РФ, 2022 67. Jolles H, Henry DA, Roberson JP, Cole TJ, Spratt JA. Mediastinitis following median sternotomy: CT findings. Radiology. 1996 Nov;201(2):463-6. 68. Doddoli C, Trousse D, Avaro JP, Djourno XB, Giudicelli R, Fuentes P, Thomas P. [Acute mediastinitis except in a context of cardiac surgery. Rev Pneumol Clin. 2010;66(1):71-80 69. Li JS, Sexton DJ, Mick N, et al. Proposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis. Clin. Infect. Dis. 2000; 30: 633–8 70. Habib G, Lancellotti P, Antunes MJ, et al. ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC)Endorsed by: European 92 Association for Cardio-Thoracic Surgery (EACTS), the European As. Eur. Heart J. 2015; 2015: 3075–128 71. Mayumi T, Yoshida M, Tazuma S, et al. The Practice Guidelines for Primary Care of Acute Abdomen 2015. Jpn. J. Radiol. 2016; 34: 80–115 72. Kiriyama S, Kozaka K, Takada T, et al. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos). J. Hepatobiliary Pancreat. Sci.2018; 25: 17–30 73. Багненко С.Ф., Савелло В.Е., Гольцов В.Р. Лучевая диагностика заболеваний поджелудочной железы: панкреатит острый / Лучевая диагностика и терапия в гастроэнтерологии: национальное руководство (гл. ред. Тома Г.Г.Кармазановский). –М.: ГЭОТАР- Медиа, 2014. – С. 349-365. 74. Leppäniemi A, Tolonen M, Tarasconi A, et al. 2019 WSES guidelines for the management of severe acute pancreatitis. World J Emerg Surg.2019; 14:27 75. Wagenlehner F.M., Lichtenstern C., Rolfes C. et al. Diagnosis and management for urosepsis// Int. J. Urol. -2013; 20: 963–70. 76. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin. Infect. Dis. 2014; 59: 147–59 77. Ferrada P. Image-based resuscitation of the hypotensive patient with cardiac ultrasound. An evidence-based review// Journal of Trauma and Acute Care Surgery.- March 2016 – vol. 80. – Issue 3. – p 511-518 doi: 10.1097/TA.0000000000000941 78. Schorr C., Odden A., Evans L. et al. Implementation of a multicenter performance improvement program for early detection and treatment of severe sepsis in general medical–surgical wards// J. Hosp. Med.- 2016; 11(S1):S32–S39 79. Dellinger R.P. The future of sepsis performance improvement. Crit Care Med. 2015.- 43(9):1787–1789 80. Damiani E., Donati A., Serafini G. et al. Effect of performance improvement programs on compliance with sepsis bundles and mortality: a systematic review and meta-analysis of observational studies// PloS One.-2015. 10(5):e0125827. Doi: 10.1371/journal.pone.0125827 81. Lie Kh.Ch, Lau Ch.-Y., Chau N.V., West T. E., Limmathurotsakul D. Utility of SOFA score, management and outcomes of sepsis in Southeast Asia: a multinational multicenter prospective observational study//Journal of Intensive Care.- 2018; 6:9. https://doi.org/10.1186/s40560-018-0279-7 82. Lambden S., Laterre P.F., Levy M.M., Francois B. The SOFA score—development, utility and challenges of accurate assessment in clinical trials//Crit Care.- 2019; 23, 374. https://doi.org/10.1186/s13054-019-2663-7 83. Астафьева М.Н., Руднов В.А., Кулабухов В.В., Багин В.А., Зубарева Н.А., Трибулёв М.А., Мухачева С.Ю. Использование шкалы qSOFA в прогнозе исхода у пациентов с сепсисом в ОРИТ (результаты российского многоцентрового исследования РИСЭС)// Вестник анестезиологии и реаниматологии. 2018;15(5):22-29. https://doi.org/10.21292/2078-5658-2018-15- 5-22-29 93 84. Kaur B., Kaur S., Yaddanapudi L.N. et al. Comparison between invasive and noninvasive blood pressure measurements in critically ill patients receiving inotropes// Blood Press Monit.- 2019; 24(1):24–29 85. Lehman L.W., Saeed M., Talmor D. et al. Methods of blood pressure measurement in the ICU//Crit Care Med.- 2013; 41(1):34–40 86. Riley L.E., Chen G.J., Latham H.E. Comparison of noninvasive blood pressure monitoring with invasive arterial pressure monitoring in medical ICU patients with septic shock// Blood Press Monit.- 2017; 22(4):202–207 87. Vincent J.-L. Arterial, central venous, and pulmonary artery catheters. In: JE P (ed) Critical care medicine: principles and diagnosis and management in the adult, 5th edn. -Elsevier, Philadelphia.- 2019; pp 40–49 88. LeDoux D., Astiz M.E., Carpati C.M. et al. Effects of perfusion pressure on tissue perfusion in septic shock // Crit Care Med.- 2000; 28(8):2729–2732 89. Osman D., Richard C., Warszawski J., Anguel N. et al; French Pulmonary Artery Catheter Study Group: Early use of the pulmonary artery catheter and outcomes in patients with shock and acute respiratory distress syndrome: a randomized controlled trial// JAMA.- 2003; 290:2713–2720 90. Shah M.R., Hasselblad V., Stevenson L.W. et al. Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials// JAMA.- 2005; 294:1664–1670 91. Connors A.F., Speroff T., Dawson N.V. et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators// JAMA.- 1996; 276:889–897 414 92. Iberti T.J., Fischer E.P., Leibowitz A.B. et al. A multicenter study of physicians’ knowledge of the pulmonary artery catheter. Pulmonary Artery Catheter Study Group// JAMA.- 1990; 264:2928–2932 93. Osman D., Richard C., Warszawski J., Anguel N. et al; French Pulmonary Artery Catheter Study Group: Early use of the pulmonary artery catheter and outcomes in patients with shock and acute respiratory distress syndrome: a randomized controlled trial// JAMA.- 2003; 290:2713–2720 94. Wheeler A.P., Bernard G.R., Thompson B.T. et al. Pulmonary artery versus central venous catheter to guide treatment of acute lung injury// N Engl J Med. - 2006;354(21):2213–2224 95. Harvey S., Harrison D.A., Singer M. et al. PAC-Man study collaboration: Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man): a andomized controlled trial// Lancet.- 2005; 366:472–477 96. Levy B. Lactate and shock state: the metabolic view// Curr Opin Crit Care.- 2006; 12(4):315–321 97. Gu W.J., Zhang Z., Bakker J. Early lactate clearance-guided therapy in patients with sepsis: a meta-analysis with trial sequential analysis of randomized controlled trials// Intensive Care Med.- 2015; 41(10):1862–1863 98. Simpson S.Q., Gaines M., Hussein Y. et al. Early goal-directed therapy for severe sepsis and septic shock: a living systematic review// J Crit Care.- 2016; 36:43–48, SSC-2021 99. Cecconi M., Hernandez G., Dunser M. et al. Fluid administration for acute circulatory dysfunction using basic monitoring: narrative review and expert panel recommendations from an ESICM task force// Intensive Care Med.- 2019; 45(1):21– 32 100. Lara B., Enberg L., Ortega M. et al. Capillary refill time during fluid resuscitation in patients with sepsis-related hyperlactatemia at the emergency department is related to mortality// PloS One.- 2017; 12(11):e0188548 101. Hernandez G., Ospina-Tascon G.A., Damiani L.P. et al. Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28-day mortality among patients with septic shock: the ANDROMEDA-SHOCK Randomized Clinical Trial// JAMA. -2019; 321(7):654–664 102. Andrews B., Semler M.W., Muchemwa L. et al. Effect of an early resuscitation protocol on in-hospital mortality among adults with sepsis and hypotension: a randomized clinical trial// JAMA.- 2017; 318(13):1233–1240 103. Shrestha G.S., Dunser M., Mer M. The forgotten value of the clinical examination to individualize and guide fluid resuscitation in patients with sepsis// Crit Care.- 2017; 21(1):306 104. Fleischmann-Struzek C., Mellhammar L., Rose N. et al. Incidence and mortality of hospital- and ICU-treated sepsis: results from an updated and expanded systematic review and meta-analysis // Intensive Care Med.- 2020; 46(8):1552–1562 105. Cherpanath T.G., Hirsch A., Geerts B.F. et al. Predicting fluid responsiveness by passive leg raising: a systematic review and meta-analysis of 23 clinical trials// Crit Care Med.- 2016; 44(5):981–991 106. Misango D., Pattnaik R., Baker T. et al. Haemodynamic assessment and support in sepsis and septic shock in resource-limited settings// Trans R Soc Trop Med Hyg.- 2017; 111(11):483–489 107. Armstrong B.A., Betzold R.D., May A.K. Sepsis and Septic Shock Strategies// Surg. Clin. North. Am.-2017; 97(6):1339-1379. Doi:10.1016/j.suc.2017.07.003 108. Heming N., Azabou E., Cazaumayou X. et al. Sepsis in the critically ill patient: current and emerging management strategies// Expert Review of Anti-infective Therapy. -2021; 19(5) :635-647. Doi: 10.1080/14787210.2021.1846522 109. De Waele J., De Bus L. How to treat infections in a surgical intensive care unit//BMC. Infect. Dis.-2014;14:193. Doi: 10.1186/1471-2334-14- 193 110. Zhou X., Su L.X., Zhang J.H. et al. Rules of anti-infection therapy for sepsis and septic shock// Chin Med J (Engl). – 2019; 132(5):589-596. Doi: 10.1097/CM9.0000000000000101 111. De Waele J.J. Early source control in sepsis// Langenbeck’s Arch. Surg. 2010; 395: 489–94 112. Bloos F., Ruddel H., Thomas-Ruddel D. et al MEDUSA study group. Effect of a multifaceted educational intervention for anti-infectious measures on sepsis mortality: A cluster randomized trial// Intensive Care Med. -2017; 43:1602–1612 113. Kim H., Chung S.P., Choi S.H. et al. Impact of timing to source control in patients with septic shock: a prospective multi-center observational study// J Crit Care.-2019; 53:176–182 95 114. Martinez M.L., Ferrer R., Torrents E. et al. Impact of Source Control in Patients With Severe Sepsis and Septic Shock//Crit Care Med.- 2017; 45(1):11–19 115. Azuhata T., Kinoshita K., Kawano D. et al. Time from admission to initiation of surgery for source control is a critical determinant of survival in patients with gastrointestinal perforation with associated septic shock// Crit Care. -2014; 18(3):R87 116. Bloos F., Thomas-Ruddel D., Ruddel H. et al. Impact of compliance with infection management guidelines on outcome in patients with severe sepsis: a prospective observational multi-center study// Crit Care.- 2014; 18(2):R42]. 117. Buck D.L., Vester-Andersen M., Moller M.H. Surgical delay is a critical determinant of survival in perforated peptic ulcer//Br J Surg.- 2013; 100(8):1045– 1049 118. Chao W.N., Tsai C.F., Chang H.R. et al. Impact of timing of surgery on outcome of Vibrio vulnificus-related necrotizing fasciitis// Am J Surg.- 2013; 206(1):32–39 119. Karvellas C.J., Abraldes J.G., Zepeda-Gomez S. et al. The impact of delayed biliary decompression and anti-microbial therapy in 260 patients with cholangitisassociated septic shock// Aliment Pharmacol Ther.- 2016; 44(7):755–766 120. Moss R.L., Musemeche C.A., Kosloske A.M. Necrotizing fasciitis in children: prompt recognition and aggressive therapy improve survival// J Pediatr Surg. -1996; 31(8):1142–1146 121. Wong C.H., Chang H.C., Pasupathy S. et al. Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality// J Bone Joint Surg Am. -2003; 85(8):1454–1460 122. Rhodes A., Evans L.E., Alhazzani W. et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016//Crit Care Med. -2017; 45(3):486–552 123. Rhodes A., Evans L.E., Alhazzani W. et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016// Intensive Care Med. -2017; 43(3):304–377 124. Jimenez M.F., Marshall J.C., International Sepsis F. Source control in the management of sepsis// Intensive Care Med.- 2001; 27(Suppl 1):S49-62 125. Хирургические инфекции кожи и мягких тканей. Российские национальные рекомендации. 2-е переработанное и дополненное издание. Б.Р. Гельфанд и коллектив авторов. М, 2015.- 111 с. 126. Острый парапроктит. Клинические рекомендации. Одобрено научнопрактическим советом Министерства здравоохранения РФ.- 2021.- 29 с., 127. Sartelli M., Guirao X., Hardcastle T.C. et al. 2018 WSES/SIS-E consensus conference: recommendations for the management of skin and soft-tissue infections// World J Emerg Surg. -2018; 13:58 128. Sartelli M.,Coccolini F., Kluger Y. et al. WSES/GAIS/WSIS/SIS-E/AAST global clinical pathways for patients with skin and soft tissue infections// World J Emerg Surg.- 2022;17(1):3 129. Инфекция, ассоциированная с ортопедическими имплантами. Клинические рекомендации. Общероссийская общественная организация Ассоциация травматологов-ортопедов России.- 101 с. (не утверждены МЗ РФ) 96 https://storage.yandexcloud.net/ator/uploads/public/601/3e0/f1d/6013e0f1da23787 5822168.pdf 130. Остеомиелит. Клинические рекомендации. Общероссийская общественная организация Ассоциация травматологов-ортопедов России. -2016. https://medi.ru/klinicheskie-rekomendatsii/osteomielit_14120, 393 – Тихилов Р.М., Божкова С.А., Артюх В.А. Перипротезная инфекция в области крупных суставов конечностей // Ортопедия. Клинические рекомендации / под ред. Акад. РАН Миронова С.П. ;Москва. – 2018. – с. 719–746, 394 – van der Bruggen W. И др. PET and SPECT in Osteomyelitis and Prosthetic Bone and Joint Infections: A Systematic Review (2010) Seminars in Nuclear Medicine. 2010. Т. 40, № 1. С. 3–15 131. Argenson J.N. et al. Hip and Knee Section, Treatment, Debridement and Retention of Implant: Proceedings of International Consensus on Orthopedic Infections // J. Arthroplasty. – 2019. -Т. 34, № 2. С. S399–S419 132. Periimplant infection – clinical guideline review http://erepo.unud.ac.id/id/eprint/30891/1/67cf9b17388264bfcc16f494780ddc13.pd f, 133. Metsemakers W.J. et al. () Fracture-related infection: A consensus on definition from an international expert group// Injury. Elsevier Ltd, - 2018. -Т. 49, № 3. С. 505–510 134. Sartelli, M., Chichom-Mefire, A., Labricciosa, F.M. et al. The management of intraabdominal infections from a global perspective: 2017 WSES guidelines for management of intraabdominalinfections// World J Emerg Surg.- 2017;12:29 135. Острый перитонит. Национальные клинические рекомендации. -2017. – 91 с. http://xn----9sbdbejx7bdduahou3a5d.xn–p1ai/upload/nkr_peritonit_ispr_1-3.pdf 136. Inukai K., Usui A., Yamada M. et al. Open abdominal management for perforative peritonitis with septic shock: a retrospective analysis on usefulness of a standardized treatment protocol// Eur J Trauma Emerg Surg.-2021; 47, 93–98. 137. Дивертикулярная болезнь Клинические рекомендации.- 2021. Одобрено Научно-практическим Советом Минздрава РФ. – 48с. 138. Острый холецистит. Клинические рекомендации.- 2021. Одобрено Научнопрактическим Советом Минздрава РФ.- 58с., 123 – Прободная язва. Клинические рекомендации.- 2021. Одобрено Научно-практическим Советом Минздрава РФ.- 54 с. 139. Прободная язва. Клинические рекомендации.- 2021. Одобрено Научнопрактическим Советом Минздрава РФ.- 54 с. 140. Корольков А.Ю. Критерии диагностики и лечебная тактика при остром холангите и билиарном сепсисе: взгляд с современных позиций / А.Ю. Корольков, Д.Н. Попов, М.А. Китаева, А.О. Танцев // Вестник Российской Военно-Медицинской Академии. – 2019. - №1. – С. 40-43 141. Lavillegrand J.-R., Mercier-Des-Rochettes E., Baron E., Pène F. et al. Acute cholangitis in intensive care units: clinical, biological, microbiological spectrum and risk factors for mortality: a multicenter study// Critical Care, BioMed Central.- 2021; 25 (1), pp.49, 126 – Mohan R., Pal Partha and Nageshwar D. Endoscopic 97 management of acute cholangitis as a result of common bile duct stones// Digestive Endoscopy.- 2017; 29 (Suppl. 2): 78–87 142. Mohan R., Pal Partha and Nageshwar D. Endoscopic management of acute cholangitis as a result of common bile duct stones// Digestive Endoscopy.- 2017; 29 (Suppl. 2): 78–87 143. Острый панкреатит. Клинические рекомендации.- 2020. Одобрено Научнопрактическим Советом Минздрава РФ. – 66 с. 144. van Brunschot S., van Grinsven J., van Santvoort H.C. et al. Endoscopic or surgical step-up approach for infected necrotizing pancreatitis: a multicentre andomized trial// Lancet.- 2018; 391: 51–8 145. Hollemans R.A., Bakker O.J., Boermeester M.A. et al. Superiority of step-up approach vs open necrosectomy in longterm follow-up of patients with necrotizing pancreatitis// Gastroenterology.- 2019; 156: 1016–26 146. Sinonquel P., Laleman W., Wilmer A. Advances in acute pancreatitis// Curr Opin Crit Care. -2021; 1;27(2):193-200. Doi: 10.1097/MCC.0000000000000806 147. Клинические рекомендации по диагностике и лечению воспалительных заболеваний позвоночника и спинного мозга, 14.10.2015, Красноярск, Ассоциация нейрохирургов России 148. Клинические рекомендации по диагностике и лечению абсцессов головного мозга, внутричерепных, эпидуральных и субдуральных эмпием. Утверждены на Пленуме Правления Ассоциации нейрохирургов России г. СанктПетербург, 16.04.2015 г.Москва, 2015.- 28с 149. Berbari E.F., Kanj S.S., Kowalski T.J. et al. Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults// Clin Infect Dis. – 2015.-61(6):e26-46 150. Отит средний острый Клинические рекомендации.- 2021. Одобрено Научнопрактическим Советом Минздрава РФ.- 49 с. 151. Паратонзиллярный абсцесс. Клинические рекомендации. -2021. Одобрено Научно-практическим Советом Минздрава РФ.- 45 с 152. Смирнова Н. А. Диагностика, лечение и прогнозирование сепсиса у больных гнойно-воспалительными заболеваниями лор-органов: дис. … канд.мед.наук. – Научно-исслед. Клинич. Ин-т оториноларингологии, 2015 153. Вennett, S., Meghji, S., Syeda, F., & Bhat, N. Neurological Complications of Acute Rhinosinusitis: Meningitis// Allergy & Rhinology. -2021; 12, 215265672199625. Doi:10.1177/2152656721996258; 154. Turhal G., Eraslan S., Kaya İ., Midilli R., Karcı B., Göde S. Procalcitonin Levels in Chronic Rhinosinusitis //Turk Arch Otorhinolaryngol. – 2019; Sep;57(3):113-116. Doi: 10.5152/tao.2019.4343. Epub 2019 Sep 1. PMID: 31620691 155. Пальчун В. Оториноларингология. Национальное руководство. ГЭОТАРМедиа.- 2020. 1012 с. 156. Akopov A., Egorov V., Furak J. Bacterial lung infections. In: ESTS textbook of Thoracic Surgery. Ed. J.Kuzdzal.- Krakow, 2014.- P.517-521 157. Григорьев Е.Г. Острый абсцесс и гангрена легкого / Е. Г. Григорьев, В. И. Капорский // Лекции по госпитальной хирургии: в 3-х томах /под ред. Е.Г. 98 Григорьева. – Иркутск: Иркутский научный центр хирургии и травматологии, 2016. – С. 94-111 158. Эмпиема плевры. Клиника, диагностика, лечение / Е. А. Цеймах, А. В. Левин, А. М. Самуйленков [и др.]; ФАЗСР РФ; ГОУ ВПО АГМУ. – Барнаул: Алтайский государственный медицинский университет Минздрава России.- 2006. – 49 с. 159. Абакумов М.М. Медиастинит. Медицинская книга.- 2020.- 296 с 160. Инфекционный эндокардит и инфекция внутрисердечных устройств//Российские клинические рекомендации. – 2021. – https://cr.minzdrav.gov.ru/andomize/54_2 161. Nagpal A., Sohail M., Steckelberg J.M. Prosthetic valve endocarditis: state of the heart// Clin Invest.- 2012; 2:803–17 162. Funakoshi S., Kaji S., Yamamuro A. et al. Impact of early surgery in the active phase on long-term outcomes in left-sided native valve infective endocarditis// J Thorac Cardiovasc Surg.- 2011; 142: 836–42 163. Lalani T., Chu V.H., Park L.P. et al. In-hospital and 1–year mortality in patients undergoing early surgery for prosthetic valve endocarditis// JAMA Intern Med.- 2013; 173:1495–504 164. Attaran S., Chukwuemeka A., Punjabi P.P. et al. Do all patients with prosthetic valve endocarditis need surgery? //Interact Cardiovasc Thorac Surg.- 2012;15:1057– 61 165. Athan E., Chu V.H., Tattevin P. et al. Clinical characteristics and outcome of infective endocarditis involving implantable cardiac devices// JAMA.- 2012;307:1727–35 166. Ye X. Incidence and costs of bleeding-related complications in French hospitals following surgery for various diagnoses// BMC health services research. - 2013;13:1:186 167. Dohmen P.M., Gabbieri D., Weymann A. et al. Reduction in surgical site infection in patients treated with microbial sealant prior to coronary artery bypass graft surgery: a case-control study//J Hosp Infect.-2009; 72:119–26 168. Grauhan O., Navasardyan A., Tutkun B. et al. Effect of surgical incision management on wound infections in a poststernotomy patient population// Int Wound J.-2014; 11(Suppl 1):6–9 169. Kowalewski M., Pawliszak W., Zaborowska K. et al. Gentamicin-collagen sponge reduces the risk of sternal wound infections after heart surgery: metaanalysis// J Thorac Cardiovasc Surg.- 2015;149:1631–40.e6 170. Острый пиелонефрит, российское общество урологов.- 2019. Урология. Российские клинические рекомендации / под ред. Ю. Г. Аляева, П. В. Глыбочко, Д. Ю. Пушкаря. — М. : ГЭОТАР- Медиа, 2016. — 496 с. 171. Акушерство и гинекология. Клинические рекомендации //ред. В.Н.Серова, Г.Т.Сухих//. 4-е изд., перераб. И доп. – М. – 2014.-1024 c 172. Септические осложнения в акушерстве. Клинические рекомендации (протокол лечения /письмо МЗ РФ от 06.02.2017 г. №15-4/10/2 -728/. https://legalacts.ru/doc/pismo-minzdrava-rossii-ot-06022017-n-15-4102-728-onapravlenii 99 173. Акушерство и гинекология. Стандарты медицинской помощи / сост. А.С. Дементьев и др./. -2-е изд., испр. И доп.- М. : ГЭОТАР-Медиа. – 2017. – 1040 с 174. Акушерство. Национальное руководство /ред. Г. М. Савельева, Г. Т. Сухих, В. Н. Серов, В. Е. Радзинский/. – 2-е изд., перераб. И доп. – М.: ГЭОТАР-Медиа. -2019. – 1080 с 175. Гинекология. Национальное руководство /ред. Савельева Г.М., Сухих Г.Т., Серов В.Н., РадзинскийВ.Е., Манухин И.Б./. -2017. – 1040 c. 176. Воспалительные болезни женских тазовых органов. Клинические рекомендации. МЗ РФ. -2021.- 46с. https://cr.minzdrav.gov.ru/clin_recomend 177. Pelvic Inflammatory Disease Management Guidelines.2017. The New Zealand Sexual Health Society 178. Brun J.L, Castan B., de Barbeyrac B., Cazanave C., Charvériat A., Faure K., Mignot S., Verdon R., Fritel X., Graesslin O.; CNGOF; SPILF. Pelvic inflammatory diseases: Updated French guidelines //J Gynecol Obstet Hum Reprod. -2020. – (5):101714. Doi: 10.1016/j.jogoh.2020.101714. Epub 2020 Feb 20. PMID: 32087306 179. Solomkin J.S., Mazuski J.E., Bradley J.S. et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America//Clin Infect Dis. -2010; 50(2):133–164 180. Mermel L.A., Allon M., Bouza E. et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America// Clin Infect Dis. -2009; 49(1):1–45 181. Lorente L., Martin M.M., Vidal P. et al. Should central venous catheter be systematically removed in patients with suspected catheter related infection?// Crit Care. -2014; 18(5):564 182. Rothrock S.G., Cassidy D.D., Barneck M., et al. Outcome of immediate versus early antibiotics in severe sepsis and septic shock: a systematic review and meta-analysis// Annals of Emergency Medicine. -2020; 76(4):427-441 183. Ferrer R., Artigas A., Suarez D. et al.; Edusepsis Study Group. Effectiveness of treatments for severe sepsis: A prospective, multicenter, observational study// Am J Respir Crit Care Med. -2009; 180:861–866 184. Liu V.X., Fielding-Singh V., Greene J.D. et al. The timing of early antibiotics and hospital mortality in sepsis//Am J Respir Crit Care Med. -2017; 196:856–863 185. Kalil A.C., Johnson D.W., Lisco S.J. et al. Early goal-directed therapy for sepsis: A novel solution for discordant survival outcomes in clinical trials//Crit Care Med. - 2017; 45:607–614 186. Branch-Elliman W., O’Brien W., Strymish J. et al. Association of duration and type of surgical prophylaxis with antimicrobial-associated adverse events// JAMA Surg. -2019; 154:590–598 187. Teshome B.F., Vouri S.M., Hampton N. et al. Duration of exposure to antipseudomonal β-lactam antibiotics in the critically ill and development of new resistance//Pharmacotherapy. -2019; 39:261–270 100 188. Tamma P.D., Avdic E., Li D.X. et al. Association of adverse events with antibiotic use in hospitalized patients// JAMA Intern Med. -2017; 177:1308–1315 189. Seymour C.W., Gesten F., Prescott H.C. et al. Time to treatment and mortality during mandated emergency care for sepsis// N Engl J Med. -2017; 376:2235–2244 190. Peltan I.D., Brown S.M., Bledsoe J.R. et al. ED door-to-antibiotic time and longterm mortality in sepsis// Chest. -2019; 155:938–946 191. Ko B.S., Choi S.H., Kang G.H. et al. Korean Shock Society (KoSS) Investigators. Time to antibiotics and the outcome of patients with septic shock: A propensity score analysis// Am J Med. -2020; 133:485–491.e4 192. Abe T., Kushimoto S., Tokuda Y. et al. JAAM FORECAST group. Implementation of earlier antibiotic administration in patients with severe sepsis and septic shock in Japan: A descriptive analysis of a prospective observational study// Crit Care. -2019; 23:360 193. Gaieski D.F., Mikkelsen M.E., Band R.A. et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department// Crit Care Med. -2010; 38:1045– 1053 194. Ryoo S.M., Kim W.Y., Sohn C.H. et al. Prognostic value of timing of antibiotic administration in patients with septic shock treated with early quantitative resuscitation// Am J Med Sci. -2015; 349:328–333 195. Puskarich M.A., Trzeciak S., Shapiro N.I. et al. Emergency Medicine Shock Research Network (EMSHOCKNET). Association between timing of antibiotic administration and mortality from septic shock in patients treated with a quantitative resuscitation protocol// Crit Care Med. -2011; 39:2066–2071 196. Weinberger J, Rhee C, Klompas M. A critical analysis of the literature on time-toantibiotics in suspected sepsis. J Infect Dis. 2020; 222(Suppl 2):S110–S118 197. Alam N., Oskam E., Stassen P.M. et al. PHANTASi Trial Investigators and the ORCA (Onderzoeks Consortium Acute Geneeskunde) Research Consortium the Netherlands. Prehospital antibiotics in the ambulance for sepsis: A multicentre, open label, andomized trial// Lancet Respir Med. -2018; 6:40–50 198. Gasch O., Camoez M., Dominguez M.A. et al. REIPI/GEIH Study Groups. Predictive factors for mortality in patients with methicillin-resistant Staphylococcus aureus bloodstream infection: Impact on outcome of host, microorganism and therapy// Clin Microbiol Infect. -2013; 19:1049–1057 199. Gasch O., Camoez M., Domínguez M.A. et al. REIPI/GEIH Study Groups. Predictive factors for early mortality among patients with methicillin-resistant Staphylococcus aureus bacteraemia// J Antimicrob Chemother. -2013; 68:1423– 1430 200. Lodise T.P., McKinnon P.S., Swiderski L. et al. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia// Clin Infect Dis. -2003; 36:1418–1423 201. Schramm G.E., Johnson J.A., Doherty J.A. et al. Methicillin-resistant Staphylococcus aureus sterile-site infection: The importance of appropriate initial antimicrobial treatment// Crit Care Med. -2006; 34:2069–2074 101 202. Griffin A.T., Peyrani P., Wiemken T.L. et al. Empiric therapy directed against MRSA in patients admitted to the intensive care unit does not improve outcomes in community-acquired pneumonia// Infection. -2013; 41:517–523 203. Yoon Y.K., Park D.W., Sohn J.W. et al. Effects of inappropriate empirical antibiotic therapy on mortality in patients with healthcare-associated methicillin-resistant Staphylococcus aureus bacteremia: A propensity-matched analysis// BMC Infect Dis. -2016; 16:331 204. Gómez J., García-Vázquez E., Baños R. Et al. Predictors of mortality in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: The role of empiric antibiotic therapy// Eur J Clin Microbiol Infect Dis. -2007; 26:239–245 205. Fang C.T., Shau W.Y., Hsueh P.R. et al. Early empirical glycopeptide therapy for patients with methicillin-resistant Staphylococcus aureus bacteraemia: Impact on the outcome// J Antimicrob Chemother. -2006; 57:511–519 206. Kim S.H., Park W.B., Lee K.D. et al. Outcome of inappropriate initial antimicrobial treatment in patients with methicillin-resistant Staphylococcus aureus bacteraemia// J Antimicrob Chemother. -2004; 54:489–497 207. Khatib R., Saeed S., Sharma M. et al. Impact of initial antibiotic choice and delayed appropriate treatment on the outcome. Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Investigators. Implementation of guidelines for management of possible multidrugresistant pneumonia in intensive care: An observational, multicentre cohort study// Lancet Infect Dis. -2011; 11:181–189 208. Rhee C., Kadri S.S., Dekker J.P. et al. CDC Prevention Epicenters Program. Prevalence of antibiotic-resistant pathogens in culture-proven sepsis and outcomes associated with inadequate and broad-spectrum empiric antibiotic use// JAMA Netw Open. -2020; 3:e202899 209. Sjövall F., Perner A., Hylander Møller M. Empirical mono- versus combination antibiotic therapy in adult intensive care patients with severe sepsis – a systematic review with meta-analysis and trial sequential analysis// J Infect. -2017; 74:331–344 210. Brunkhorst F.M., Oppert M., Marx G. et al. German Study Group Competence Network Sepsis (SepNet). Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: A randomized trial// JAMA. -2012; 307:2390–2399 211. Мониторинг антибиотикорезистентности с использованием платформы AMRcloud. Практическое руководство. Под ред. Член-кор. РАН Р.С. Козлова; отв.ред. А.Г. Виноградова, А.Ю. Кузьменков, И.В. Труши – Смоленск: СГМУ, 2021 – 160 с. ISBN 978-5-9903685-9-0// 212. Rottier W.C., Bamberg Y.R., Dorigo-Zetsma J.W. et al. Predictive value of prior colonization and antibiotic use for third-generation cephalosporin-resistant andomizediaceae bacteremia in patients with sepsis// Clin Infect Dis. -2015; 60:1622–1630 213. Alevizakos M., Karanika S., Detsis M. et al. Colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae and risk for infection among patients with solid or haematological malignancy: A systematic review and meta-analysis// Int J Antimicrob Agents. -2016; 48:647–654 214. Pappas P.G., Kauffman C.A., Andes D.R. et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America// Clin Infect Dis. -2016; 62:e1–50 215. Magill S.S., Edwards J.R., Bamberg W. et al.; Emerging Infections Program HealthcareAssociated Infections and Antimicrobial Use Prevalence Survey Team. Multistate pointprevalence survey of health care-associated infections// N Engl J Med. 2014; 370:1198– 1208 216. Bassetti M., Righi E., Ansaldi F. et al. A multicenter study of septic shock due to candidemia: Outcomes and predictors of mortality// Intensive Care Med. -2014; 40:839–845 217. Kollef M., Micek S., Hampton N. et al. Septic shock attributed to Candida infection: Importance of empiric therapy and source control// Clin Infect Dis. -2012; 54:1739– 1746 218. Garey K.W., Rege M., Pai M.P. et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study// Clin Infect Dis. -2006; 43:25–31 219. Morrell M., Fraser V.J., Kollef M.H. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: A potential risk factor for hospital mortality// Antimicrob Agents Chemother. -2005; 49:3640– 3645 220. Timsit J.F., Azoulay E., Schwebel C. et al. EMPIRICUS Trial Group. Empirical micafungin treatment and survival without invasive fungal infection in adults with ICU-acquired sepsis, candida colonization, and multiple organ failure: The EMPIRICUS randomized clinical trial// JAMA. -2016; 316:1555–1564 221. Веселов А.В., Козлов Р.С.. Инвазивный кандидоз: современные аспекты эпидемиологии, диагностики, терапии и профилактики у различных категорий пациентов. // Клиническая микробиология и антимикробная химиотерапия. – 2016; Т.18. №2 (приложение). С.1-102. Pappas P.G., Kauffman C.A., Andes D.R., Clancy C.J., Marr K.A., et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. // Clinical Infectious Diseases. – 2016; 62(4):e1-50. Doi: 10.1093/cid/civ933 222. Freifeld A.G., Bow E.J., Sepkowitz K.A. et al.; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America// Clin Infect Dis. -2011; 52:e56–e93 223. Goncalves-Pereira J., Povoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of beta-lactams// Crit Care. -2011; 15(5):R206 224. Roberts J.A., Abdul-Aziz M.H., Davis J.S. et al. Continuous versus intermittent beta-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials// Am J Respir Crit Care Med.- 2016; 194(6):681–691 225. Roberts J.A., Abdul-Aziz M.H., Davis J.S. et al. Continuous versus intermittent beta-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials// Am J Respir Crit Care Med.- 2016; 194(6):681–691 226. Goncalves-Pereira J., Povoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of beta-lactams// Crit Care. -2011; 15(5):R206 103 227. De Waele J.J., Lipman J., Carlier M. et al. Subtleties in practical application of prolonged infusion of beta-lactam antibiotics// Int J Antimicrob Agents. -2015; 45(5):461–463 228. Lipman J., Brett S.J., De Waele J.J. et al. A protocol for a phase 3 multicentre andomized controlled trial of continuous versus intermittent beta-lactam antibiotic infusion in critically ill patients with sepsis: BLING III// Crit Care Resusc. -2019; 21(1):63–68 229. Cheng V., Abdul-Aziz M.H., Roberts J.A. et al. Overcoming barriers to optimal drug dosing during ECMO in critically ill adult patients// Expert Opin Drug Metab Toxicol. -2019; 15(2):103–112 230. Guilhaumou R., Benaboud S., Bennis Y. et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patientsguidelines from the French Society of Pharmacology and Therapeutic (Societe Francaise de Pharmacologie et Therapeutique-SFPT) and theFrench Society of Anaesthesia and Intensive Care Medicine (Societe Francaise d’Anesthesie et Reanimation-SFAR)// Crit Care. - 2019; 23(1):104 231. Roberts J.A., Abdul-Aziz M.H., Lipman J. et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions// Lancet Infect Dis. -2014; 14(6):498–509 232. Veiga R.P., Paiva J.A. Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients// Crit Care. -2018; 22(1):233 233. Nelson N.R., Morbitzer K.A., Jordan J.D. et al. The impact of capping creatinine clearance on achieving therapeutic vancomycin concentrations in neurocritically ill patients with traumatic brain injury// Neurocrit Care.- 2019; 30(1):126–131 234. Gregoire N., Marchand S., Ferrandiere M. et al. Population pharmacokinetics of daptomycin in critically ill patients with various degrees of renal impairment// J Antimicrob Chemother. -2019; 74(1):117–125 235. Ulldemolins M., Roberts J.A., Rello J. et al. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients// Clin Pharmacokinet. -2011; 50(2):99–110 236. Roberts J.A., Joynt G., Lee A. et al. The effect of renal replacement therapy and antibiotic dose on antibiotic concentrations in critically ill patients: data from the multinational SMARRT Study// Clin Infect Dis. -2020; 72(8):1369–1378 237. Bougle A., Dujardin O., Lepere V. et al. PHARMECMO: Therapeutic drug monitoring and adequacy of current dosing regimens of antibiotics in patients on Extracorporeal Life Support// Anaesth Crit Care Pain Med. -2019; 38(5):493–497 238. Cheng V., Abdul-Aziz M.H., Roberts J.A. et al. Overcoming barriers to optimal drug dosing during ECMO in critically ill adult patients// Expert Opin Drug Metab Toxicol. -2019; 15(2):103–112 239. Guilhaumou R., Benaboud S., Bennis Y. et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patientsguidelines from the French Society of Pharmacology and Therapeutic (Societe Francaise de Pharmacologie et Therapeutique-SFPT) and theFrench Society of Anaesthesia and Intensive Care 104 Medicine (Societe Francaise d’Anesthesie et Reanimation-SFAR)// Crit Care. - 2019; 23(1):104 240. Wong G., Taccone F., Villois P. et al. beta-Lactam pharmacodynamics in Gramnegative bloodstream infections in the critically ill// J Antimicrob Chemother. - 2020; 75(2):429–433 241. Fleuren L.M., Roggeveen L.F., Guo T. et al. Clinically relevant pharmacokinetic knowledge on antibiotic dosing among intensive care professionals is insufficient: a cross-sectional study// Crit Care. -2019; 23(1):185 242. Ehmann L., Zoller M., Minichmayr I.K. et al. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis// Int J Antimicrob Agents. -2019; 54(3):309–317 243. Williams P., Beall G., Cotta M.O. et al. Antimicrobial dosing in critical care: a pragmatic adult dosing nomogram// Int J Antimicrob Agents. -2020; 55(2):105837 244. Arulkumaran N., Routledge M., Schlebusch S. et al. Antimicrobialassociated harm in critical care: a narrative review// Intensive Care Med. -2020; 46(2):225–235 245. Tabah A., Bassetti M., Kollef M.H. et al. Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP)// Intensive Care Med. -2020; 46(2):245–265 246. Leone M., Bechis C., Baumstarck K. et al. De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial// Intensive Care Med. -2014; 40(10):1399–1408 247. De Bus L., Depuydt P., Steen J. et al. Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: the DIANA study// Intensive Care Med. -2020; 46(7):1404–141 248. Fernandez-Lazaro C.I., Brown K.A., Langford B.J. et al. Late-career physicians prescribe longer courses of antibiotics// Clin Infect Dis.-2019; 69(9):1467–1475 249. Sawyer R.G., Claridge J.A., Nathens A.B. et al. Trial of short-course antimicrobial therapy for intraabdominal infection// N Engl J Med. -2015; 372(21):1996–2005 250. Corona A., Bertolini G., Ricotta A.M. et al. Variability of treatment duration for bacteraemia in the critically ill: a multinational survey// J Antimicrob Chemother. - 2003; 52(5):849–852 251. Wald-Dickler N., Spellberg B. Short-course antibiotic therapyreplacing andomized units with “Shorter Is Better.”//Clin Infect Dis. -2019; 69(9):1476–1479 252. Klompas M., Calandra T., Singer M. Antibiotics for sepsis-finding the equilibrium// JAMA.- 2018; 320(14):1433–1434 253. Prescott H.C., Iwashyna T.J. Improving sepsis treatment by embracing diagnostic uncertainty// Ann Am Thorac Soc. -2019; 16(4):426–429 254. Kalil A.C., Metersky M.L., Klompas M. et al. Management of adults with hospitalacquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American Thoracic Society// Clin Infect Dis. -2016; 63(5):e61–e111 105 255. Vaughn V.M., Flanders S.A., Snyder A. et al. Excess antibiotic treatment duration and adverse events in patients hospitalized with pneumonia: a multihospital cohort study// Ann Intern Med. -2019; 171(3):153–163 256. Eliakim-Raz N., Yahav D., Paul M. et al. Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection—7 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials// J Antimicrob Chemother. -2013; 68(10):2183–2191 257. Yahav D., Franceschini E., Koppel F. et al. Seven versus 14 days of antibiotic therapy for uncomplicated gram-negative bacteremia: a noninferiority randomized controlled Trial// Clin Infect Dis.-2019; 69(7):1091–1098 258. Sawyer R.G., Claridge J.A., Nathens A.B. et al. Trial of short-course antimicrobial therapy for intraabdominal infection// N Engl J Med. -2015; 372(21):1996–005 259. Fernandez-Lazaro C.I., Brown K.A., Langford B.J. et al. Late-career physicians prescribe longer courses of antibiotics// Clin Infect Dis. -2019; 69(9):1467–1475 260. Corona A., Bertolini G., Ricotta A.M. et al. Variability of treatment duration for bacteraemia in the critically ill: a multinational survey// J Antimicrob Chemother. -2003; 52(5):849–852 261. Minderhoud T.C., Spruyt C., Huisman S. et al. Microbiological outcomes and antibiotic overuse in Emergency Department patients with suspected sepsis// Neth J Med. -2017; 75(5):196–203 262. Klein Klouwenberg P.M., Cremer O.L., van Vught L.A. et al. Likelihood of infection in patients with presumed sepsis at the time of intensive care unit admission: a cohort study// Crit Care.-2015; 19:319 263. Tidswell R., Parker T., Brealey D. et al. Sepsis–the broken code how accurately is sepsis being diagnosed? //J Infect. -2020; 81(6):e31–e32 264. Annane D., Siami S., Jaber S. et al. Effects of fluid resuscitation with colloids vs crystalloids on mortality in critically ill patients presenting with hypovolemic shock: the CRISTAL randomized trial// JAMA.- 2013; 310(17):1809–1817 265. Chen C., Kollef M.H. Targeted fluid minimization following initial resuscitation in septic shock: A pilot study// Chest. -2015; 148:1462–1469 266. Corl K.A., Prodromou M., Merchant RC. Et al. The restrictive IV fluid trial in severe sepsis and septic shock (RIFTS): A randomized pilot study// Crit Care Med. -2019; 47:951–959 267. Hjortrup P.B., Haase N., Bundgaard H. et al. CLASSIC Trial Group; Scandinavian Critical Care Trials Group. Restricting volumes of resuscitation fluid in adults with septic shock after initial management: The CLASSIC andomized, parallelgroup, multicentre feasibility trial//Intensive Care Med. -2016; 42:1695–1705 268. Macdonald S.P.J., Keijzers G., Taylor D.M. et al. REFRESH trial investigators. Restricted fluid resuscitation in suspected sepsis associated hypotension (REFRESH): A pilot andomized controlled trial// Intensive Care Med. -2018; 44:2070–2078 269. Semler M.W., Janz D.R., Casey J.D. et al. Conservative fluid management after sepsis resuscitation: A pilot randomized trial// J Int Care Med. -2019; 35:1374–1382 270. Rowan K.M., Angus D.C., Bailey M. et al. Early, goal-directed therapy for septic shock.- A patient-level meta-analysis// N Engl J Med. -2017; 376:2223–2234 106 271. Marik P.E., Lemson J. Fluid responsiveness: An evolution of our understanding// Br J Anaesth.- 2014.- vol. 112.- P. 620–622 272. Marik P., Belomo R. A rational approach to fluid therapy in sepsis//Br. J. Anaesth. – 2016; Mar;116(3):339-49. Doi: 10.1093/bja/aev349 273. Samoni S. Impact of hyperhydration on the mortality risk in critically ill patients admitted in intensive care units: comparison between bioelectrical impedance vector analysis and cumulative fluid balance recording// Critical Care. – 2016.- 20:95 274. Rochwerg B., Alhazzani W., Sindi A. et al. Fluids in Sepsis and Septic Shock Group. Fluid resuscitation in sepsis: A systematic review and network metaanalysis// Ann Intern Med. -2014; 161:347–355 275. Semler M.W., Self W.H., Wanderer J.P. et al. SMART Investigators and the Pragmatic Critical Care Research Group. Balanced crystalloids versus saline in critically ill adults// N Engl J Med. -2018; 378:829–839 276. Brown R.M., Wang L., Coston T.D. et al. Balanced crystalloids versus saline in sepsis. A secondary analysis of the SMART clinical trial// Am J Respir Crit Care Med. -2019; 200:1487–1495 277. Kuttab H.I., Lykins J.D., Hughes M.D. et al. Evaluation and predictors of fluid resuscitation in patients with severe sepsis and septic shock// Crit Care Med. -2019; 47:1582–1590 278. Delaney A., Dan P., McCaffrey A., Simon F. The role of albumin as a resuscitation fluid for patients with sepsis: A systematic review and meta-analysis// Critical Care Medicine.- February 2011; vol. 39 – Issue 2 – p 386-391 279. Wiedermann C., Joannidis M. Albumin Replacement in Severe Sepsis or Septic Shock //N Engl J Med. -2014; 371:83-84 280. Martin G.S., Bassett P. Crystalloids vs. colloids for fluid resuscitation in the intensive care unit: A systematic review and meta-analysis// J Crit Care. -2019; 50:144–154 281. Park C.H.L., de Almeida J.P., de Oliveira G.Q. et al. Lactated Ringer’s versus 4% albumin on lactated Ringer’s in early sepsis therapy in cancer patients: A pilot single-center randomized trial// Crit Care Med. -2019; 47:e798–e805 282. Kakaei F.H.S., Asheghvatan A., Zarrintan S. et al. Albumin as a resuscitative fluid in patients with severe sepsis: A randomized clinical trial// Adv Biosci Clin Med. - 2017; 5:9–16 283. Vincent J-L., De Backer D., Wiedermann C.J. Fluid management in sepsis: The potential beneficial effects of albumin// J Crit Care. -2016 Oct;35:161-7 284. Deutschman C.S., Tracey K.J. Sepsis: current dogma and new perspectives// Immunity.- 2014.- Vol.40 (4).- P. 463-475 285. Распоряжение Минздрава России № 20-3/41 от 11.01.2017 г с дополнением Росздравнадзора № 05-63525/18 от 22.11.2018 г 286. Rochwerg B., Alhazzani W., Gibson A. et al. Fluid type and the use of renal replacement therapy in sepsis: a systematic review and network meta-analysis// Intensive Care Med.- 2015; 41(9):1561–1571 287. Moeller C., Fleischmann C., Thomas-Rueddel D. et al. How safe is gelatin? A systematic review and meta-analysis of gelatin-containing plasma expanders vs crystalloids and albumin// J Crit Care.- 2016; 35:75–83 107 288. Hébert P.C., Wells G., Blajchman M.A. et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care// N Eng J Med. -1999; 340:409–417 289. Holst L.B., Haase N., Wetterslev J. et al. TRISS Trial Group; Scandinavian Critical Care Trials Group. Lower versus higher hemoglobin threshold for transfusion in septic shock// N Engl J Med. -2014; 371:1381–139 290. Hirano Y., Miyoshi Y., Kondo Y. et al. Liberal versus restrictive red blood cell transfusion strategy in sepsis or septic shock: A systematic review and meta-analysis of randomized trials// Crit Care. -2019; 23:262 291. Bergamin F.S., Almeida J.P., Landoni G. et al. Liberal versus restrictive transfusion strategy in critically ill oncologic patients: The transfusion requirements in critically ill oncologic patients randomized controlled trial// Crit Care Med. -2017; 45:766– 773 292. ANDROMEDA-SHOCK Randomized Clinical Trial.”//JAMA.- 2019; vol. 321,7: 654-664 293. Ospina-Tascón G.A., Hernandez G., Alvarez I. et al. Effects of very early start of norepinephrine in patients with septic shock: a propensity score-based analysis// Crit Care. -2020 Feb 14; 24 (1):52 294. Asfar P., Meziani F., Hamel J.F. et al. High versus low blood-pressure target in patients with septic shock// N Engl J Med.-2014; 370(17):1583–1593 295. Hylands M., Moller M.H., Asfar P. et al. A systematic review of vasopressor blood pressure targets in critically ill adults with hypotension// Can J Anaesth. -2017; 64(7):703–715 296. Lamontagne F., Meade M.O., Hebert P.C .et al. Higher versus lower blood pressure targets for vasopressor therapy in shock: a multicentre pilot randomized controlled trial// Intensive Care Med.- 2016; 42(4):542–550 297. Lamontagne F., Richards-Belle A., Thomas K. et al. Effect of reduced exposure to vasopressors on 90-day mortality in older critically ill patients with vasodilatory hypotension: a randomized clinical trial// JAMA. -2020; 323(10):938–949 298. Avni T., Lador A., Lev S. et al. Vasopressors for the treatment of septic shock: systematic review and meta-analysis// PloS One. -2015; 10(8):e0129305 299. Bellomo R., Chapman M., Hickling K., Myburgh J. Low-dose dopamine in patiets with early renal dysfunction: a placebo controlled randomized trial.// Australian and New Aealeand intensive care society (ANZICS) clinical trials group. Lancet.- 2000; 356:2139-2143 300. Regnier B., Safran D., Carlet J. et al. Comparative haemodynamic effects of dopamine and dobutamine in septic shock// Intensive Care Med. -1979; 5(3):115– 120 301. Bhattacharjee S., Soni K.D., Maitra S. et al. Levosimendan does not provide mortality beneft over dobutamine in adult patients with septic shock: a meta-analysis of randomized controlled trials// J Clin Anesth. -2017; 39:67–72 302. Belletti A., Benedetto U., Biondi-Zoccai G., Leggieri C., Silvani P., Angelini G.D., Zangrillo A., Landoni G. The effect of vasoactive drugs on mortality in patients with severe sepsis and septic shock. A network meta-analysis of randomized trials// Journal of Critical Care.- 2017; vol. 37, р. 91-98 108 303. Meng J.B., Hu M.H., Lai Z.Z. et al. Levosimendan Versus Dobutamine in Myocardial Injury Patients with Septic Shock: A Randomized Controlled Trial//Med Sci Monit. -2016; 22:1486-1496. Published 2016 May 3. Doi:10.12659/msm.898457 304. Liu D.H., Ning Y.L., Lei, Yan Y.Y., Chen J., Liu Y.Y., Lin X.F., Yang Zh.Q., Xian Sh.X., Chen W.T. Levosimendan versus dobutamine for sepsis-induced cardiac dysfunction: a systematic review and meta-analysis (2021)//https://www.nature.com/articles/s41598-021-99716-9 305. Gordon A.C., Perkins G.D., Singer M. et al. Levosimendan for the prevention of acute organ dysfunction in sepsis// N Engl J Med.-2016; 375(17):1638–1648 306. Girardis M., Busani S., Damiani E. et al. Effect of Conservative vs conventional oxygentherapy on mortality among patients in an intensive care unit: the oxygenICU randomized clinical trial// JAMA.- 2016; 316(15):1583–1589 307. Chu D.K., Kim L.H., Young P.J. et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis// Lancet.- 2018; 391(10131):1693–1705 308. New Zealand Intensive Care Society Clinical Trials et al. Conservative Oxygen Therapy during Mechanical Ventilation in the ICU// N Engl J Med.- 2020; 382(11):989–998 309. Panwar R., Hardie M., Bellomo R. et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients. A pilot multicenter randomized controlled trial// Am J Respir Crit Care Med. -2016; 193(1):43–51 310. Barrot L, Asfar P, Mauny F et al (2020) Liberal or conservative oxygen therapy for acute respiratory distress syndrome. N Engl J Med 382(11):999–1008 311. Mauri T., Turrini C., Eronia N. et al. Physiologic effects of high-flow nasal cannula in acute hypoxemic respiratory failure// Am J Respir Crit Care Med. -2017; 195(9):1207–121 312. Frat J.P., Thille A.W., Mercat A. et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure// N Engl J Med. -2015; 372(23):2185–2196 313. Fleischmann C., Scherag A., Adhikari N.K. et al. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations// Am J Respir Crit Care Med. -2016; 193(3):259–272 314. Ni Y.N., Luo J., Yu H. et al. The effect of high-flow nasal cannula in reducing the mortality and the rate of endotracheal intubation when used before mechanical ventilation compared with conventional oxygentherapy and noninvasive positive pressure ventilation. A systematic review and meta-analysis// Am J Emerg Med. - 2018; 36(2):226–233 315. Ou X., Hua Y., Liu J. et al. Effect of high-flow nasal cannula oxygen therapy in adults with acute hypoxemic respiratory failure: a metaanalysis of randomized controlled trials// CMAJ. – 2017; 189(7):E260–E267 316. Rochwerg B., Granton D., Wang D.X. et al. High-flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure: author’s reply// Intensive Care Med. -2019; 45(8):1171 109 317. Demoule A., Chevret S., Carlucci A. et al. Changing use of noninvasive ventilation in critically ill patients: trends over 15 years in francophone countries// Intensive Care Med. -2016; 42(1):82–92. 318. Demoule A., Girou E., Richard J.C. et al. Benefits and risks of success or failure of noninvasive ventilation// Intensive Care Med. – 2006; 32(11):1756–1765 319. Bellani G., Laffey J.G., Pham T. et al. Noninvasive ventilation of patients with acute respiratory distress syndrome. Insights from the LUNG SAFE Study// Am J Respir Crit Care Med. -2017; 195(1):67–77 320. Antonelli M., Conti G., Rocco M. et al. A comparison of noninvasive positivepressure ventilation and conventional mechanical ventilation in patients with acute respiratory failure// N Engl J Med. – 1998; 339(7):429–435 321. Honrubia T., Garcia Lopez F.J., Franco N. et al. Noninvasive vs conventional mechanical ventilation in acute respiratory failure: a multicenter, randomized controlled trial// Chest. -2005; 128(6):3916–3924 322. Tonelli R., Fantini R., Tabbi L. et al. Early inspiratory effort assessment by esophageal manometry predicts noninvasive ventilation outcome in de novo respiratory failure. A pilot study// Am J Respir Crit Care Med. -2020; 202(4):558– 567 323. Brower R.G., Matthay M.A. et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome// N Engl J Med.- 2000; 342(18):1301–1308 324. Amato M.B., Barbas C.S., Medeiros D.M. et al. Effect of a protectiveventilation strategy on mortality in the acute respiratory distress syndrome// N Engl J Med. - 1998; 338(6):347–354 426 325. Brochard L., Roudot-Thoraval F., Roupie E. et al. Tidal volume reduction for prevention of ventilator-induced lung injury in acute respiratory distress syndrome. The Multicenter Trail Group on Tidal Volume reduction in ARDS// Am J Respir Crit Care Med. -1998; 158(6):1831–1838 326. Force A.D.T., Ranieri V.M., Rubenfeld G.D. et al. Acute respiratory distress syndrome: the Berlin Definition// JAMA.- 2012; 307(23):2526–2533 327. Brower R.G., Shanholtz C.B., Fessler H.E. et al. Prospective, randomized, controlled clinical trial comparing traditional versus reduced tidal volume ventilation in acute respiratory distress syndrome patients// Crit Care Med . – 1999; 27(8):1492–1498 328. Brower R.G., Matthay M.A. et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome// N Engl J Med.- 2000; 342(18):1301–1308 329. Papazian L., Aubron C., Brochard L. et al. Formal guidelines: management of acute respiratory distress syndrome// Ann Intensive Care. -2019; 9(1):69 330. Eichacker P.Q., Gerstenberger E.P., Banks S.M. et al. Meta-analysis of acute lung injury and acute respiratory distress syndrome trials testing low tidal volumes// Am J Respir Crit Care Med.-2002; 166(11):1510–1514 331. Burns K.E.A., Adhikari N.K., Slutsky A.S. et al. Pressure and volume limited ventilation for the ventilatory management of patients with acute lung injury: a systematic review and meta-analysis// PloS One, -2011; 6 (1):e14623 110 332. Putensen C., Theuerkauf N., Zinserling J., Wrigge H., Pelosi P. Meta-analysis: ventilation strategies and outcomes of the acute respiratory distress syndrome and acute lung injury// Ann Intern Med. -2009; 151(8):566–576 333. Marini J.J., Gattinoni L. Ventilatory management of acute respiratory distress syndrome: a consensus of two// Crit Care Med.-2004; 32(1):250–255 334. Hager D.N., Krishnan J.A., Hayden D.L. et al. Tidal volume reduction in patients with acute lung injury when plateau pressures are not high// Am J Respir Crit Care Med. -2005; 172(10):1241–1245 335. Checkley W., Brower R., Korpak A. et al. Effects of a clinical trial on mechanical ventilation practices in patients with acute lung injury// Am J Respir Crit Care Med. -2008;177(11):1215–1222 336. Laffey J.G., Bellani G., Pham T. et al. Potentially modifiable factors contributing to outcome from acute respiratory distress syndrome: the LUNG SAFE study// Intensive Care Med. -2016; 42(12):1865–1876 337. Bernard G.R., Artigas A., Brigham K.L. et al. The American-European Consensus Conference on ARDS definitions, mechanisms, relevant outcomes, and clinical trial coordination// Am J Respir Crit Care Med.-1994; 149(3Pt 1):818–824 338. Villar J., Martin-Rodriguez C., Dominguez-Berrot A.M. et al. A quantile analysis of plateau and driving pressures: effects on mortality in patients with acute respiratory distress syndrome receiving lungprotective ventilation// Crit Care Med.- 2017;45(5):843–850 339. Brower R.G., Lanken P.N., MacIntyre N. et al. Higher versus lower positive endexpiratory pressures in patients with the acute respiratory distress syndrome// N Engl J Med. -2004; 351(4):327–336 340. Meade M.O., Cook D.J., Guyatt G.H. et al. Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive endexpiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized controlled trial// JAMA. -2008; 299(6):637–645 341. Mercat A., Richard J.C., Vielle B. et al. Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial// JAMA. -2008; 299(6):646–655 342. Kacmarek R.M., Villar J., Sulemanji D. et al. Open lung approach for the acute respiratory distress syndrome: a pilot randomized controlled trial// Crit Care Med. - 2016; 44(1):32–42 343. Briel M., Meade M., Mercat A. et al. Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: systematic review and meta-analysis// JAMA.-2010; 303(9):865–873 344. Goligher EC, Kavanagh BP, Rubenfeld GD et al. Oxygenation response to positive end-expiratory pressure predicts mortality in acute respiratory distress syndrome. A secondary analysis of the LOVS and ExPress trials// Am J Respir Crit Care Med.- 2014; 190(1):70–76 345. Amato M.B., Barbas C.S., Medeiros D.M. et al. Beneficial effects of the “open lung approach” with low distending pressures in acute respiratory distress syndrome. A prospective randomized study on mechanical ventilation//Am J Respir Crit Care Med. -1995; 152(6 Pt 1):1835–1846 111 346. Gattinoni L., Caironi P., Cressoni M. et al. Lung recruitment in patients with the acute respiratory distress syndrome// N Engl J Med. -2006; 354(17):1775–1786 347. Beitler J.R., Sarge T., Banner-Goodspeed V.M. et al. Effect of titrating positive endexpiratory pressure (PEEP) with an esophageal pressure-guided strategy vs an empirical high PEEP-Fio2 strategy on death and days free from mechanical ventilation among patients with acute respiratory distress syndrome: a randomized clinical trial// JAMA. -2019; 321(9):846–857 348. Talmor D., Sarge T., Malhotra A. et al. Mechanical ventilation guided by esophageal pressure in acute lung injury// N Engl J Med. -2008; 359(20):2095–2104 349. Turbil E., Galerneau L.M., Terzi N. et al Positive-end expiratory pressure titration and transpulmonary pressure: the EPVENT 2 trial// J Thorac Dis. -2019; 11(Suppl 15):S2012–S2017 350. Serpa Neto A., Cardoso S.O., Manetta J.A. et al. Association between use of lungprotective ventilation with lower tidal volumes and clinical outcomes among patients without acute respiratory distress syndrome: a meta-analysis// JAMA. - 2012; 308(16):1651–1659 351. Pipeling M.R., Fan E. Therapies for refractory hypoxemia in acute respiratory distress syndrome// JAMA.-2010; 304(22):2521–2527 352. Cavalcanti A.B., Suzumura É.A., Laranjeira L.N. et al. Effect of lung recruitment and titrated positive end-expiratory pressure (PEEP) vs low PEEP on mortality in patients with acute respiratory distress syndrome: a randomized clinical trial// JAMA. -2017; 318(14):1335–1345 353. Hodgson C.L., Cooper D.J., Arabi Y. et al. Maximal recruitment open lung ventilation in acute respiratory distress syndrome (PHARLAP). A phase II, multicenter randomized controlled clinical trial// Am J Respir Crit Care Med. -2019; 200(11):1363–1372 354. Fan E., Wilcox M.E., Brower R.G. et al. Recruitment maneuvers for acute lung injury a systematic review// Am J Respir Crit Care Med. -2008; 178(11):1156–1163 355. Munshi L., Del Sorbo L., Adhikari N.K.J. et al. Prone position for acute respiratory distress syndrome. A systematic review and meta-analysis// Ann Am Thorac Soc.- 2017; 14(Supplement_4):S280-s8 356. Jolliet P., Bulpa P., Chevrolet J.C. Effects of the prone position on gas exchange and hemodynamics in severe acute respiratory distress syndrome// Crit Care Med. - 1998; 26(12):1977–1985 357. Lamm W.J., Graham M.M., Albert R.K. Mechanism by which the prone position improves oxygenation in acute lung injury// Am J Respir Crit Care Med. -1994; 150(1):184–193 358. Stocker R., Neff T., Stein S. et al. Prone postioning and low-volume pressurelimited ventilation improve survival in patients with severe ARDS// Chest.- 1997; 111(4):1008–1017 359. Gattinoni L., Tognoni G., Pesenti A. et al. Effect of prone positioning on the survival of patients with acute respiratory failure// N Engl J Med. -2001; 345(8):568–573 360. Guerin C., Gaillard S., Lemasson S. et al. Effects of systematic prone positioning in hypoxemic acute respiratory failure: a randomized controlled trial// JAMA. -2004; 292(19):2379–2387 112 361. Papazian L., Forel J.M., Gacouin A. et al. Neuromuscular blockersin early acute respiratory distress syndrome// N Engl J Med. -2010; 363(12):1107–1116 362. Lyu G., Wang X., Jiang W. et al. Clinical study of early use of neuromuscular blocking agents in patients with severe sepsis and acute respiratory distress syndrome// Zhonghua Wei Zhong Bing Ji Jiu Yi Xue.-2014; May;26(5):325-9. Doi: 10.3760/cma.j.issn.2095-4352.2014.05.008 363. Moss M. et al. Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome// N Engl J Med. -2019; 380(21):1997–2008 364. Alhazzani W., Belley-Cote E., Moller M.H. et al. Neuromuscular blockade in patients with ARDS: a rapid practice guideline// Intensive Care Med. -2020; 46(11): 1977–1986, doi: 10.1007/s00134-020-06227-8 365. Klessig H.T., Geiger H.J., Murray M.J. et al. A National Survey on the practice patterns of anesthesiologist intensivists in the use of musclerelaxants// Crit Care Med. -1992; 20(9):1341–1345 366. Murray M.J., Cowen J., DeBlock H. et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient// Crit Care Med.-2002; 30(1):142–156 367. Hansenflaschen J.H., Brazinsky S., Basile C. et al. USE OF sedating drugs and neuromuscular blocking-agents in patients requiring mechanical ventilation for respiratory-failure—a National Survey// JAMA. -1991; 266(20):2870–2875 368. Forel J.M., Roch A., Marin V. et al. Neuromuscular blocking agents decrease inflammatory response in patients presenting with acute respiratory distress syndrome// Crit Care Med.- 2006; 34(11):2749–2757 369. Gainnier M., Roch A., Forel J.M. et al. Effect of neuromuscular blocking agents on gas exchange in patients presenting with acute respiratory distress syndrome// Crit Care Med. -2004; 32(1):113–119. 370. Alhazzani W., Alshahrani M., Jaeschke R. et al. Neuromuscular blocking agents in acute respiratory distress syndrome: a systematicreview and meta-analysis of randomized controlled trials// Crit Care. -2013; 17(2):R43 371. Guervilly C., Bisbal M., Forel J.M. et al. Effects of neuromuscular blockers on transpulmonary pressures in moderate to severe acute respiratory distress syndrome// Intensive Care Med. -2017; 43(3):408–418 372. Lyu G., Wang X., Jiang W. et al. Clinical study of early use of neuromuscular blocking agents in patients with severe sepsis and acute respiratory distress syndrome// Zhonghua Wei Zhong Bing Ji Jiu Yi Xue.-2014; May;26(5):325-9. doi: 10.3760/cma.j.issn.2095- 4352.2014.05.008 373. Moss M. et al. Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome// N Engl J Med. -2019; 380(21):1997–2008 374. Alhazzani W., Belley-Cote E., Moller M.H. et al. Neuromuscular blockade in patients with ARDS: a rapid practice guideline// Intensive Care Med. -2020; 46(11): 1977– 1986, doi: 10.1007/s00134-020-06227-8 375. Tarazan N., Alshehri M., Sharif S. et al. Neuromuscular blocking agents in acute respiratory distress syndrome: updated systematic review and meta-analysis of randomized trials// Intensive Care Med Exp. -2020; 8(1):61 376. Johnson K.L., Cheung R.B., Johnson S.B. et al. Therapeutic paralysis of critically ill trauma patients: perceptions of patients and their family members// Am J Crit Care. -1999; 8(1):490–498 377. Munshi L., Walkey A., Goligher E. et al. Venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: a systematic review and metaanalysis// Lancet Respir Med. -2019; 7(2):163–172 378. Combes A., Hajage D., Capellier G. et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome// N Engl J Med. -2018; 378(21):1965–1975 379. Peek G.J., Mugford M., Tiruvoipati R. et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre andomized controlled trial// Lancet. -2009; 374(9698):1351–1363 380. Klein D.J., Foster D., Walker P.M., Bagshaw S.M., Mekonnen H., Antonelli M. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial// Intensive Care Med. - 2018; Dec;44(12):2205-2212. Doi: 10.1007/s00134-018-5463-7. Epub 2018 Nov 23. PMID: 30470853; PMCID: PMC6280819 381. Fujimori K., Tarasawa K, Fushimi K. Effectiveness of polymyxin B hemoperfusion for sepsis depends on the baseline SOFA score: a nationwide observational study//Ann. Intensive Care. -2021; 11, 141. https://doi.org/10.1186/s13613-021- 00928 382. Saito A., Kawanishi H., Yamashita A.C., Mineshima M. (eds). High-performance membrane dialyzers //Contrib Nephrol. Basel, Karger. -2011. – V. 173, p. 182–190 383. Snow T.A.C., Littlewood S., Corredor C., Singer M., Arulkumaran N. Effect of Extracorporeal Blood Purification on Mortality in Sepsis: A Meta-Analysis and Trial Sequential Analysis// Blood Purification. -2020; 1–11 384. Brouwer W.P., Duran S., Kuijper M., Ince C. Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study // Crit Care. – 2019. - 18;23(1):317. PMID: 31533846; PMCID: PMC6749645. https://doi.org/10.1186/s13054-019-2588-1 https://pubmed.ncbi.nlm.nih.gov/31533846/ 385. Rugg C, Klose R., Hornung R., Innerhofer N., Bachler M., Schmid S., Fries D., Ströhle M. Hemoadsorption with Cytosorb in septic shock reduces catecholamine requirements and in-hospital mortality: A Single-Center Retrospective 'Genetic' Matched Analysis // Biomedicines. -2020. - 26;8(12):539. PMID: 33255912; PMCID: PMC7760738. https://doi.org/10.3390/biomedicines8120539 https://pubmed.ncbi.nlm.nih.gov/33255912/ 386. Rimmer E., Houston B.L., Kumar A. et al. The efficacy and safety of plasma exchange in patients with sepsis and septic shock: a systematic review and metaanalysis//Crit Care. -2014. -18. - P.699. doi: 10.1186/s13054-014-0699-2 387. Keith PD, Wells AH, Hodges J, et al. The therapeutic efficacy of adjunct therapeutic plasma exchange for septic shock with multiple organ failure: a single-center experience / Critical Care.-2020.- 24:518. doi.org/10.1186/s13054-020-03241-6 114 388. Kishikawa, T., Fujieda, H. & Sakaguchi, H. Comprehensive analysis of cytokine adsorption properties of polymethyl methacrylate (PMMA) membrane material. J Artif Organs (2022). https://doi.org/10.1007/s10047-022-01323-6 389. Lumlertgul N, Srisawat N. The haemodynamic effects of oXiris haemofilter in septic shock patients requiring renal support: A single-centre experience. Int J Artif Organs. 2021 Jan;44(1):17-24. doi: 10.1177/0391398820917150. Epub 2020 May 11. PMID: 32393096 390. Padmanabhan A., Connelly-Smith L., Aqui N. et al. Guidelines on the use of therapeutic apheresis in clinical practice –evidence-based approach from the Writing Committee of the American Society for Apheresis: the eighth special issue //J Clin Apher. – 2019. - 34:171–354 391. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. Journal of Hepatology 2017, 66(5), 1047– 1081. doi:10.1016/j.jhep.2016.12.003 392. Zha J., Li C., Cheng G. et al. The efficacy of renal replacement therapy strategies for septic-acute kidney injury: a PRISMA-compliant network metaanalysis. Medicine (Baltimore). -2019; 98(16):e15257. doi: 10.1097/MD.0000000000015257 393. Zhao Y., Chen Y.. Effect of renal replacement therapy modalities on renal recovery and mortality for acute kidney injury: A PRISMA-compliant systematic review and meta-analysis//Semin Dial. -2020;33(2):127–132. doi: 10.1111/sdi.12861 394. Murugan R., Kerti S. J., Chang C-H, Gallagher M., Neto A. S., Clermont G., Ronco C., Palevsky P., M, Kellum J.A., Bellomo R. association between net ultrafiltration rate and renal recovery among critically ill adults with acute kidney injury receiving continuous renal replacement therapy: an observational cohort study// Blood Purif. - 2022; 51:397-409. doi: 10.1159/000517281 395. Gaudry S., Hajage D., Schortgen F. et al. Initiation strategies for renal-replacement therapy in the intensive care unit// N Engl J Med. -2016;375(2):122–133. doi: 10.1056/NEJMoa1603017 396. Barbar S.D., Clere-Jehl R., Bourredjem A. et al. Timing of renal-replacement therapy in patients with acute kidney injury and sepsis// N Engl J Med. -2018; 379(15):1431–1442. doi: 10.1056/NEJMoa1803213 397. Clinical practice guidelines for acute kidney injury. - 2012. http://www.kdigo.org/clinical_practice_guidelines/AKI.php 398. Rabindranath K, Adams J, Macleod AM, et al. Intermittent versus continuous renal replacement therapy for acute renal failure in adults. Cochrane Database Syst Rev 2007: CD003773 399. Ye Z, Wang Y, Ge L, Guyatt GH, Collister D, Alhazzani W, Bagshaw SM, BelleyCote EP, Fang F, Hou L, Kolb P, Lamontagne F, Oczkowski S, Pyne L, Rabbat C, Scaum M, Najafabadi BT, Tangamornsuksan W, Wald R, Wang Q, Walsh M, Yao L, Zeng L, Algarni AM, Couban RJ, Alexander PE, Rochwerg B. Comparing Renal Replacement Therapy Modalities in Critically Ill Patients With Acute Kidney Injury: A Systematic Review and Network Meta-Analysis. Crit Care Explor. 2021 May 115 400. Davenport A. Continuous renal replacement therapies in patients with acute neurological injury// Semin Dial. - 2009; 22: 165–168 401. Bagshaw S.M., Peets A.D., Hameed M. et al. Dialysis Disequilibrium Syndrome: brain death following hemodialysis for metabolic acidosis and acute renal failure–a case report// BMC Nephrol. - 2004; 5: 9 402. Lin C.M., Lin J.W., Tsai J.T. et al. Intracranial pressure fluctuation during hemodialysis in renal failure patients with intracranial hemorrhage//Acta Neurochir Suppl. - 2008; 101: 141–144 403. Murugan R, Kerti SJ, Chang CH, et al. Association of Net Ultrafiltration Rate With Mortality Among Critically Ill Adults With Acute Kidney Injury Receiving Continuous Venovenous Hemodiafiltration: A Secondary Analysis of the Randomized Evaluation of Normal vs Augmented Level (RENAL) of Renal Replacement Therapy Trial. JAMA Netw Open. 2019;2(6):e195418. doi:10.1001/jamanetworkopen.2019.5418 404. Murugan R, Kerti S, J, Chang C, -C, H, Gallagher M, Neto A, S, Clermont G, Ronco C, Palevsky P, M, Kellum J, A, Bellomo R: Association between Net Ultrafiltration Rate and Renal Recovery among Critically Ill Adults with Acute Kidney Injury Receiving Continuous Renal Replacement Therapy: An Observational Cohort Study. Blood Purif 2022;51:397-409. doi: 10.1159/000517281 405. Investigators S-A, Canadian Critical Care Trials G, Australian et al. Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury. N Engl J Med. 2020;383(3):240–251. doi: 10.1056/NEJMoa2000741 406. Gaudry S., Hajage D., Martin-Lefevre L, Lebbah S., Louis G., Moschietto S., Titeca-Beauport D., Combe B., Pons B., de Prost N., Besset S., Combes A., Robine A., Beuzelin M., Badie J., Chevrel G., Bohé J., Coupez .E, Chudeau N., Barbar S., Vinsonneau C., Forel J.M., Thevenin D., Boulet E., Lakhal K., Aissaoui N., Grange S., Leone M., Lacave G., Nseir S., Poirson F., Mayaux J., Asehnoune K., Geri G., Klouche K., Thiery G., Argaud L., Rozec B., Cadoz C., Andreu P., Reignier J., Ricard J.D., Quenot J.P., Dreyfuss D. Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2): a multicentre, open-label, randomised, controlled trial //Lancet – 2021. - 3;397(10281):1293-1300. doi: 10.1016/S0140-6736(21)00350-0. PMID: 33812488 407. Rygård S.L., Butler E., Granholm A. et al. Low-dose corticosteroids for adult patients with septic shock: A systematic review with meta-analysis and trial sequential analysis// Intensive Care Med. -2018; 44:1003–1016 408. Wong H.R., Cvijanovich N. Z., Anas N., Allen G. L., Thomas N. J., Bigham M. T., Weiss S. L., Fitzgerald J., Checchia P. A., Meyer K., Shanley T. P., Quasney M., Hall M., Gedeit R., Freishtat R.J., Nowak J., Shekhar R.S., Gertz S., Dawson E., Howard K., Lindsell C.J. Developing a clinically feasible personalized medicine approach to pediatric septic shock// American journal of respiratory and critical care medicine. -2015; 191(3), 309–315 409. Sprung, Charles L. MD; Brezis, Mayer MD; Goodman, Serge MD, PhD; Weiss, Yoram G. MD Corticosteroid therapy for patients in septic shock: Some progress in a difficult decision, Critical Care Medicine: March 2011 - Volume 39 - Issue 3 - p 571-574 116 410. Wong, H. R., Cvijanovich, N. Z., Anas, N., Allen, G. L., Thomas, N. J., Bigham, M. T., Weiss, S. L., Fitzgerald, J., Checchia, P. A., Meyer, K., Shanley, T. P., Quasney, M., Hall, M., Gedeit, R., Freishtat, R. J., Nowak, J., Shekhar, R. S., Gertz, S., Dawson, E., Howard, K., … Lindsell, C. J. (2015). Developing a clinically feasible personalized medicine approach to pediatric septic shock. American journal of respiratory and critical care medicine, 191(3), 309–315 411. Annane D, Renault A, Brun-Buisson C, et al.; CRICS-TRIGGERSEP Network. Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med. 2018; 378:809–818 412. Marik P.E. Corticosteroids for septic shock: what to do now? //J Emerg Crit Care Med.- 2018;2:34 413. Kreymann K.G., de Heer G., Nierhaus A., Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock// Crit Care Med. - 2007 Dec;35(12):2677-85 414. Arabi Y.M., Al-Hameed F., Burns K.E.A. et al. Saudi Critical Care Trials Group. Adjunctive intermittent pneumatic compression for venous thromboprophylaxis// N Engl J Med. -2019; 380:1305–1315 415. Iba T., Levy J.H., WarkentinTh.E., Thachil J., Poll T., Levi M. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation// J Thromb Haemost. -2019 nov; 17 (11):1989-1994. doi: 10.1111/jth.14578 416. Iba T., Gando S., Thachil J. Anticoagulant therapy for sepsis-associated disseminated intravascular coagulation: the view from Japan// J Thromb Haemost. - 2014 Jul;12(7):1010-9. doi: 10.1111/jth.12596. Epub 2014 Jun 19. PMID: 24801203 417. Umemura Y., Yamakawa K., Ogura H., Yuhara H., Fujimi S. Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials// J Thromb Haemost. - 2016 Mar;14(3):518-30. doi: 10.1111/jth.13230. Epub 2016 Feb 1. PMID: 26670422 418. Kienast J., Juers M., Wiedermann C.J., Hoffmann J.N., Ostermann H., Strauss R., Keinecke H.O., Warren B.L, Opal S.M. KyberSept investigators. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation// J Thromb Haemost. -2006 Jan; 4(1):90-7. doi: 10.1111/j.1538-7836.2005.01697.x 419. Dhainaut J.F., Yan S.B., Joyce D.E., Pettilä V., Basson B., Brandt J.T., Sundin D.P., Levi M. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation// J Thromb Haemost. -2004 Nov; 2(11):1924-33. doi: 10.1111/j.1538-7836.2004.00955.x 420. Wada H., Thachil J., Di Nisio M., Mathew P., Kurosawa S., Gando S. et al. Guidance for diagnosis and treatment of disseminated intravascular coagulation from harmonization of the recommendations from three guidelines//J Thromb Haemost. 2013;11:761-7 421. Warren B.L., Eid A., Singer P., Pillay S.S., Carl P., Novak I. et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis, a randomized controlled trial//JAMA. -2001; 286:1869-78 117 422. Levy J.H., Sniecinski R.M., Welsby I.J., Levi M. Antithrombin: anti-inflammatory properties and clinical applications// Thromb Haemost. - 2016;115:712-28 423. Интенсивная терапия: национальное руководство в 2 т. / под ред. Б.Р. Гельфанда, А.И. Салтанова. М.: ГОЭТАР-Медиа, 2011. Т.1. 960 с 424. Levi M., Toh C.H., Thachil J., Watson H.G. Guidelines for the diagnosis and management of disseminated intravascular coagulation// British Journal of Haematology. -2009; 145, 24–33. doi: 10.1111/j.1365-2141.2009.07600.x 425. The NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients// N Engl J Med. -2009;360(13):1283–1297 426. Barbara Wo´jcik . Jerzy Superata . H. Bryant Nguyen . Zbigniew Szyguła. Exploration of Different Rehabilitation Routes for Sepsis Survivors with Monitoring of Health Status and Quality of Life: RehaSep Trial Protocol //Adv Ther (2019) 36:2968–2978 https://doi.org/10.1007/s12325-019-01047-9 427. Zhang K, Mao X, Fang Q, Jin Y, Cheng B, Xie G, Li H, Yu L, Zhu T, Wang H, Liu X, Zhang Y, Jin Y, Zhang N, Lou T, Fang XM. Impaired long-term quality of life in survivors of severe sepsis : Chinese multicenter study over 6 years.//Anaesthesist. 2013 Dec;62(12):995-1002. doi: 10.1007/s00101-013-2257-8 428. Granja C, Dias C, Costa-Pereira A, Sarmento A. Quality of life of survivors from severe sepsis and septic shock may be similar to that of others who survive critical illness.Crit Care. 2004 Apr;8(2):R91-8. doi: 10.1186/cc2818. Epub 2004 Feb 20 429. Ya-Xiao Su, Lei Xu, Xin-Jing Gao, Zhi-Yong Wang , Xing Lu, Cheng-Fen Yin. Long-term quality of life after sepsis and predictors of quality of life in survivors with sepsis // Chinese Journal of Traumatology/ Volume 21, Issue 4, August 2018, Pages 216-223/ https://doi.org/10.1016/j.cjtee.2018.05.001 430. Sakai Y., Yamamoto S., Karasawa T., Sato M., Nitta K. et al. Effects of early rehabilitation in sepsis patients by a specialized physical therapist in an emergency center on the return to activities of daily living independence: A retrospective cohort study// Plos One. – 2022; 17(3): e0266348. https://doi.org/10.1371/journal.pone.0266348 431. Белкин А.А., Алашеев А.М., В.А. Белкин и др. Реабилитация в отделении реанимации и интенсивной терапии (РеабИТ). Методические рекомендации Союза реабилитологов России и Федерации анестезиологов и реаниматологов//Вестник интенсивной терапии им. Салтанова.- 2022.-№2. С.7-40, https://doi.org/10.21320/1818-474X-2022-2-7-40 432. Anekwe D. E., Biswas S., Bussières A., Spahija J. Early rehabilitation reduces the likelihood of developing intensive care unit-acquired weakness: a systematic review and meta-analysis. Physiotherapy. 2020; 107: 1–10. DOI: 10.1016/j.physio.2019.12.004 433. Connolly B., Salisbury L., O’Neill B., et al. Exercise rehabilitation following intensive care unit discharge for recovery from critical illness: executive summary of a Cochrane Collaboration systematic review. J Cachexia Sarcopenia Muscle. 2016; 7(5): 520–6. DOI: 10.1002/ jcsm.12146 434. Brissie M. A., Zomorodi M., Soares-Sardinha S., Jordan J. D. Development of a neuro early mobilisation protocol for use in a neuroscience intensive care unit. Intensive Crit Care Nurs. 2017; 42: 30–5. DOI: 10.1016/j.iccn.2017.03.007 , Mezidi 118 M., Guérin C. Effects of patient positioning on respiratory mechanics in mechanically ventilated ICU patients. Ann Transl Med. 2018; 6(19): 384. DOI: 10.21037/atm.2018.05.50 435. Vorona S., Sabatini U., Al-Maqbali S., et al. Inspiratory Muscle Rehabilitation in Critically Ill Adults. A Systematic Review and Meta-Analysis. Ann Am Thorac Soc. 2018; 15(6): 735–744. DOI: 10.1513/ AnnalsATS.201712-961OC 436. Gonzáles A. I., Vieira D. S.R., Bündchen D. C., et al. Safety criteria to start early mobilization in intensive care units. Systematic review. Rev Bras Ter Intensiva. 2018; 29(4): 509–19. DOI: 10.5935/0103-507x.20170076 437. Nydahl P., Sricharoenchai T., Chandra S., et al. Safety of Patient Mobilization and Rehabilitation in the Intensive Care Unit. Systematic Review with Meta-Analysis. Ann Am Thorac Soc. 2017; 14(5): 766– 77. DOI: 10.1513/AnnalsATS.201611- 843SR 438. Приказ Минздрава РФ от 31 июля 2020 г. №788Н «Об утверждении порядка организации медицинской реабилитации взрослых» URL: https://www.garant.ru/products/ipo/prime/doc/ 74581688/ 439. Сергеев А.Н., Морозов А.М., Аскеров Э.М. и др. Методы локальной антимикробной профилактики инфекции области хирургического вмешательства Казанский мед. ж. 2020; 101 (2): 243–248. DOI: 10.17816/ KMJ2020-243 440. Брико Н.И., Божкова С.А., Брусина Е.Б., Жедаева М.В., Зубарева Н.А., Зуева Л.П., Иванова Е.Б., Казачек Я.В., Квашнина Д.В., Ковалишена О.В., Кузьменко С.А., Павлов В.В., Пасечник И.Н., Попов Д.А., Цигельник А.М., Цой Е.Р., Шмакова М.А., Шубняков И.И., Яковлев С.В. Профилактика инфекций области хирургического вмеша-тельства. Клинические рекомендации. – Н. Новгород: Изд-во «Ремедиум Приволжье», 2018. – 72 с. 441. Mohr N.M., Wessman B.T., Bassin B. et al. Boarding of critically ill patients in the emergency department// Crit Care Med. -2020; 48(8):1180–1187 442. Cardoso L.T., Grion C.M., Matsuo T. et al. Impact of delayed admission to intensive care units on mortality of critically ill patients: a cohort study// Crit Care. -2011; 15(1):R28 443. Groenland C.N.L., Termorshuizen F., Rietdijk W.J.R. et al. emergency department to icu time is associated with hospital mortality: a registry analysis of 14,788 patients from six University Hospitals in The Netherlands// Crit Care Med. -2019; 47(11):1564–1571 444. Harris S., Singer M., Sanderson C. et al. Impact on mortality of prompt admission to critical care for deteriorating ward patients: an instrumental variable analysis using critical care bed strain//Intensive Care Med. -2018; 44(5):606–615 445. Heffner A.C., Horton J.M., Marchick M.R. et al. (2010) Etiology of illness in patients with severe sepsis admitted to the hospital from the emergency department. Clin Infect Dis 50(6):814–820 446. Tidswell R, Parker T, Brealey D, et al (2020) Sepsis–the broken code how accurately is sepsis being diagnosed? J Infect 81(6):e31–e32 119 447. Klein Klouwenberg PM, Cremer OL, van Vught LA et al (2015) Likelihoodof infection in patients with presumed sepsis at the time of intensive care unit admission: a cohort study. Crit Care 19:319 448. Levin PD, Idrees S, Sprung CL et al (2012) Antimicrobial use in the ICU: indications and accuracy—an observational trial. J Hosp Med 7(9):672–678 449 Rybak M.J., Le J., Lodise T.P., Levine D.P., Bradley J.S., et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Americal Journal Health-System Pharmacology. 2020;77:835-864 450 Hanai Y., Takahashi Y., Niwa T., Mayumi T., et.al. Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. Journal of Antimicrobial Chemotherapy. 2022; 77(4): 869–879 451 Holland T.L., Arnold C., Fowler V.G. Clinical Management of Staphylococcus aureus Bacteremia. JAMA. 2014; 312(13): 1330–1341 452 Cosimi R.A., Beik N., Kubiak D.W., Johnson J.A. Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review. Open Forum Infect Dis. 2017; 4(2): ofx084 453 Jones T.W., Jun A.H., Michal J.L., Olney W.J. High-dose daptomycin and clinical applications. Ann Pharmacother. 2021; 55(11): 1363–1378 454 Liapikou A., Dimakou K., Toumbis M. Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience. Ther Adv Respir Dis. 2016; 10(4): 368–378 455 Gutiérrez-Gutiérrez B., Bonomo R.A., Carmeli Y., Paterson D.L., et.al. Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. J Antimicrob Chemother. 2016; 71(6): 1672–1680 456 Bader J.C., Lakota E.A., Dale G.E., Sader H.S., et.al. Pharmacokineticpharmacodynamic evaluation of ertapenem for patients with hospital-acquired or ventilator-associated bacterial pneumonia. Antimicrob Agents Chemother. 2019; 63(6): e00318-19 457 Kothekar A.T., Divatia J.V., Myatra S.N., Patil A., et al. Clinical pharmacokinetics of 3-h extended infusion of meropenem in adult patients with severe sepsis and septic shock: Implications for empirical therapy against gram-negative bacteria. Ann. Intensive Care. 2020; 10 (1): 4. 458 Hsaiky L., Murray K. P., Kokoska L., Desai N., Cha R. Standard versus prolonged doripenem infusion for treatment of gram-negative infections. Ann. Pharmacother. 2013; 47 (7-8): 999–1006 459 Sakka S.G., Glauner A.K., Bulitta J.B., Kinzig-Schippers M., et al. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob. Agents Chemother. 2007; 51(9): 3304–3310 120 460 Paul M., Carrara E., Retamar P., Tangd T., et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli. Clinical Microbiology and Infection. 2022; 28(4): 521-547 461 Hansen M., Christrup L.L., Jarløv J.O., Kampmann J.P., Bonde J. Gentamicin dosing in critically ill patients. Acta Anaesthesiol Scand. 2001; 45(6): 734-40 462 Dimopoulos G., Koulenti D., Parker S.L., Roberts J.A., Arvaniti K., Poulakou G. Intravenous fosfomycin for the treatment of multidrug-resistant pathogens: what is the evidence on dosing regimens? Expert Rev Anti Infect Ther. 2019; 17(3): 201- 210 463 Gutiérrez-Gutiérrez B., Bonomo R.A., Carmeli Y., Paterson D.L., et.al. Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. J Antimicrob Chemother. 2016; 71(6): 1672–1680 464 De Pascale G., Montini L.,1 Pennisi M.A., Bernini V., Maviglia R., et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care. 2014; 18(3): R90 465 Tamma P.D., Aitken S.L., Bonomo R.A., Mathers A.J., van Duin D., Clancy C.J. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis. 2022; 75(2): 187–212 466 Tsuji B.T., Pogue J.M., Zavascki A.P., Paul M., et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019; 39(1): 10–39 467 de Montmollin E., Bouadma L., Gault N., Mourvillier B., Mariotte E., et al. Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen. Intensive Care Med. 2014; 40(7): 998-1005 468 Teasdale G.M., Jennett B.Assessment of coma and impaired consciousness: A practical scale. Lancet, 1974